Peter Valent

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/965483/publications.pdf

Version: 2024-02-01

748 papers	44,207 citations	1994 101 h-index	4117 175 g-index
769 all docs	769 docs citations	769 times ranked	31064 citing authors

#	Article	IF	Citations
1	Revised International Prognostic Scoring System for Myelodysplastic Syndromes. Blood, 2012, 120, 2454-2465.	1.4	2,458
2	RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature, 2011, 478, 524-528.	27.8	1,656
3	Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leukemia Research, 2001, 25, 603-625.	0.8	1,020
4	New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood, 2007, 110, 4385-4395.	1.4	719
5	Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. Journal of Allergy and Clinical Immunology, 2012, 130, 607-612.e9.	2.9	604
6	Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood, 2007, 110, 4055-4063.	1.4	600
7	Cancer stem cell definitions and terminology: the devil is in the details. Nature Reviews Cancer, 2012, 12, 767-775.	28.4	599
8	New Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia After MDS Derived From an International Database Merge. Journal of Clinical Oncology, 2012, 30, 820-829.	1.6	584
9	Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts. Blood, 2017, 129, 1420-1427.	1.4	520
10	Definitions, Criteria and Global Classification of Mast Cell Disorders with Special Reference to Mast Cell Activation Syndromes: A Consensus Proposal. International Archives of Allergy and Immunology, 2012, 157, 215-225.	2.1	513
11	Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. Leukemia Research, 2007, 31, 727-736.	0.8	478
12	Transcriptional plasticity promotes primary and acquired resistance to BET inhibition. Nature, 2015, 525, 543-547.	27.8	414
13	Mast Cells, Mastocytosis, and Related Disorders. New England Journal of Medicine, 2015, 373, 163-172.	27.0	402
14	Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis. New England Journal of Medicine, 2016, 374, 2530-2541.	27.0	383
15	Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nature Medicine, 2020, 26, 1549-1556.	30.7	372
16	Simvastatin Reduces Expression of Cytokines Interleukin-6, Interleukin-8, and Monocyte Chemoattractant Protein-1 in Circulating Monocytes From Hypercholesterolemic Patients. Arteriosclerosis, Thrombosis, and Vascular Biology, 2002, 22, 1194-1199.	2.4	340
17	Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology. Journal of Allergy and Clinical Immunology, 2016, 137, 35-45.	2.9	289
18	BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1Î±, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. Blood, 2002, 100, 3767-3775.	1.4	275

#	Article	IF	Citations
19	The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 13283-13288.	7.1	274
20	Mast cell activation syndrome: Proposed diagnostic criteria. Journal of Allergy and Clinical Immunology, 2010, 126, 1099-1104.e4.	2.9	266
21	Anemia at older age: etiologies, clinical implications, and management. Blood, 2018, 131, 505-514.	1.4	266
22	Identification of common allergenic structures in hazel pollen and hazelnuts: A possible explanation for sensitivity to hazelnuts in patients allergic to tree pollen. Journal of Allergy and Clinical Immunology, 1992, 90, 927-936.	2.9	265
23	Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. , 2022, 1, .		259
24	Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. American Journal of Hematology, 2011, 86, 533-539.	4.1	254
25	Paul Ehrlich (1854-1915) and His Contributions to the Foundation and Birth of Translational Medicine. Journal of Innate Immunity, 2016, 8, 111-120.	3.8	249
26	BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1. Cell Reports, 2017, 18, 2162-2174.	6.4	244
27	Vasoactive Intestinal Peptide-Receptor Imaging for the Localization of Intestinal Adenocarcinomas and Endocrine Tumors. New England Journal of Medicine, 1994, 331, 1116-1121.	27.0	243
28	Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors. Blood, 2015, 125, 901-906.	1.4	239
29	PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. Blood, 2006, 107, 752-759.	1.4	235
30	Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides. Blood, 2005, 105, 3303-3311.	1.4	226
31	Diagnostic Value of Immunostaining for Tryptase in Patients With Mastocytosis. American Journal of Surgical Pathology, 1998, 22, 1132-1140.	3.7	225
32	Recombinant Carp Parvalbumin, the Major Cross-Reactive Fish Allergen: A Tool for Diagnosis and Therapy of Fish Allergy. Journal of Immunology, 2002, 168, 4576-4584.	0.8	223
33	Comprehensive mutational profiling in advanced systemic mastocytosis. Blood, 2013, 122, 2460-2466.	1.4	222
34	The Basophil-Specific Ectoenzyme E-NPP3 (CD203c) as a Marker for Cell Activation and Allergy Diagnosis. International Archives of Allergy and Immunology, 2004, 133, 317-329.	2.1	218
35	Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria. Leukemia Research, 2003, 27, 635-641.	0.8	217
36	Stat5 tetramer formation is associated with leukemogenesis. Cancer Cell, 2005, 7, 87-99.	16.8	213

#	Article	IF	Citations
37	Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. European Heart Journal, 2022, 43, 280-299.	2.2	213
38	Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findings. Leukemia Research, 2001, 25, 543-551.	0.8	211
39	Mastocytosis: State of the Art. Pathobiology, 2007, 74, 121-132.	3.8	210
40	Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future. Cancer Research, 2017, 77, 1261-1270.	0.9	210
41	Morphologic properties of neoplastic mast cells: delineation of stages of maturation and implication for cytological grading of mastocytosis. Leukemia Research, 2001, 25, 529-536.	0.8	206
42	Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia. Blood, 2014, 123, 3951-3962.	1.4	189
43	Diagnosis and treatment of systemic mastocytosis: state of the art. British Journal of Haematology, 2003, 122, 695-717.	2.5	187
44	Serum Tryptase Levels in Patients with Mastocytosis: Correlation with Mast Cell Burden and Implication for Defining the Category of Disease. International Archives of Allergy and Immunology, 2002, 128, 136-141.	2.1	184
45	Cell Surface Structures on Human Basophils and Mast Cells: Biochemical and Functional Characterization. Advances in Immunology, 1992, 52, 333-423.	2.2	181
46	Mastocytosis: Pathology, genetics, and current options for therapy. Leukemia and Lymphoma, 2005, 46, 35-48.	1.3	180
47	Identification of Der p 23, a Peritrophin-like Protein, as a New Major Dermatophagoides pteronyssinus Allergen Associated with the Peritrophic Matrix of Mite Fecal Pellets. Journal of Immunology, 2013, 190, 3059-3067.	0.8	177
48	Molecular and Immunological Characterization of Arginine Kinase from the Indianmeal Moth,Plodia interpunctella, a Novel Cross-Reactive Invertebrate Pan-Allergen. Journal of Immunology, 2001, 167, 5470-5477.	0.8	176
49	High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia. Blood, 2011, 117, 3409-3420.	1.4	168
50	Implications of STAT3 and STAT5 signaling on gene regulation and chromatin remodeling in hematopoietic cancer. Leukemia, 2018, 32, 1713-1726.	7.2	166
51	A Recombinant Hypoallergenic Parvalbumin Mutant for Immunotherapy of IgE-Mediated Fish Allergy. Journal of Immunology, 2007, 178, 6290-6296.	0.8	165
52	CD25 Indicates the Neoplastic Phenotype of Mast Cells. American Journal of Surgical Pathology, 2004, 28, 1319-1325.	3.7	163
53	Diagnosis and classification of mast cell proliferative disorders: delineation from immunologic diseases and nonâ€“mast cell hematopoietic neoplasms. Journal of Allergy and Clinical Immunology, 2004, 114, 3-11.	2.9	157
54	Recombinant allergens promote expression of CD203c on basophils in sensitized individuals. Journal of Allergy and Clinical Immunology, 2002, 110, 102-109.	2.9	156

#	Article	IF	Citations
55	Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions. Oncotarget, 2017, 8, 73483-73500.	1.8	153
56	Variable presence of KIT^{D816V} in clonal haematological nonâ€mast cell lineage diseases associated with systemic mastocytosis (SMâ€“AHNMD). Journal of Pathology, 2010, 220, 586-595.	4.5	152
57	Proposed Diagnostic Algorithm for Patients with Suspected Mast Cell Activation Syndrome. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 1125-1133.e1.	3.8	150
58	Rac2-MRC-cIIIâ€“generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors. Blood, 2012, 119, 4253-4263.	1.4	147
59	Hematopoietic Stem-Cell Transplantation for Advanced Systemic Mastocytosis. Journal of Clinical Oncology, 2014, 32, 3264-3274.	1.6	146
60	Severe Peripheral Arterial Disease During Nilotinib Therapy. Journal of the National Cancer Institute, 2011, 103, 1347-1348.	6.3	145
61	Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia (AML). Oncotarget, 2012, 3, 1588-1599.	1.8	144
62	Identification of Heme Oxygenase-1 As a Novel BCR/ABL-Dependent Survival Factor in Chronic Myeloid Leukemia. Cancer Research, 2004, 64, 3148-3154.	0.9	143
63	Detection of molecular targets on the surface of CD34+/CD38â^' stem cells in various myeloid malignancies. Leukemia and Lymphoma, 2006, 47, 207-222.	1.3	140
64	Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field. Expert Review of Hematology, 2012, 5, 157-176.	2.2	140
65	Time-dependent changes in mortality and transformation risk in MDS. Blood, 2016, 128, 902-910.	1.4	140
66	Coalesced Multicentric Analysis of 2,351 Patients With Myelodysplastic Syndromes Indicates an Underestimation of Poor-Risk Cytogenetics of Myelodysplastic Syndromes in the International Prognostic Scoring System. Journal of Clinical Oncology, 2011, 29, 1963-1970.	1.6	139
67	Induction of antibody responses to new B cell epitopes indicates vaccination character of allergen immunotherapy. European Journal of Immunology, 1999, 29, 2026-2036.	2.9	138
68	Simvastatin Reduces the Expression of Adhesion Molecules in Circulating Monocytes From Hypercholesterolemic Patients. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 397-403.	2.4	138
69	Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literature. Leukemia Research, 2004, 28, 249-257.	0.8	138
70	Identification of CD13, CD107a, and CD164 as novel basophil-activation markers and dissection of two response patterns in time kinetics of IgE-dependent upregulation. Cell Research, 2005, 15, 325-335.	12.0	138
71	Mutation analysis of Câ€KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis. British Journal of Haematology, 2001, 113, 357-364.	2.5	135
72	The basophil activation marker defined by antibody 97A6 is identical to the ectonucleotide pyrophosphatase/phosphodiesterase 3. Blood, 2001, 97, 3303-3305.	1.4	134

#	Article	IF	Citations
73	Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy. Blood, 2018, 132, 694-706.	1.4	132
74	Aberrant expression of CD30 in neoplastic mast cells in high-grade mastocytosis. Modern Pathology, 2011, 24, 585-595.	5.5	131
75	Expression of mast cell tryptase by myeloblasts in a group of patients with acute myeloid leukemia. Blood, 2001, 98, 2200-2209.	1.4	130
76	Kit and <i>c-kit</i> Mutations in Mastocytosis: A Short Overview with Special Reference to Novel Molecular and Diagnostic Concepts. International Archives of Allergy and Immunology, 2002, 127, 110-114.	2.1	130
77	Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study. Lancet Haematology,the, 2017, 4, e595-e606.	4.6	130
78	Pathogenesis, classification and treatment of mastocytosis: state of the art in 2010 and future perspectives. Expert Review of Hematology, 2010, 3, 497-516.	2.2	129
79	C5a stimulates production of plasminogen activator inhibitor-1 in human mast cells and basophils. Blood, 2002, 100, 517-523.	1.4	128
80	Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal. HemaSphere, 2021, 5, e646.	2.7	128
81	Red Blood Cell Transfusion Dependence and Outcome after Allogeneic Peripheral Blood Stem Cell Transplantation in Patients with de Novo Myelodysplastic Syndrome (MDS). Biology of Blood and Marrow Transplantation, 2008, 14, 1217-1225.	2.0	126
82	Utility of flow cytometric analysis of mast cells in the diagnosis and classification of adult mastocytosis. Leukemia Research, 2001, 25, 563-570.	0.8	124
83	Immunoglobulin E Response to Human Proteins in Atopic Patients. Journal of Investigative Dermatology, 1996, 107, 203-208.	0.7	122
84	Molecular Characterization of an Autoallergen, Hom s 1, Identified by Serum IgE from Atopic Dermatitis Patients11Part of this manuscript was previously published in the proceedings of the 21st Symposium of the Collegium Internationale Allergologicum â€œAllergy â€“ A Disease of Modern Societyâ€; Int Arch Allergy Immunol 113:209â€“212, 1998. Journal of Investigative Dermatology, 1998, 111, 1178-1183.	0.7	122
85	Targeting the SH2-Kinase Interface in Bcr-Abl Inhibits Leukemogenesis. Cell, 2011, 147, 306-319.	28.9	122
86	International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis. Blood, 2013, 121, 2393-2401.	1.4	122
87	Isolation of cDNA clones coding for IgE autoantigens with serum IgE from atopic dermatitis patients. FASEB Journal, 1998, 12, 1559-1569.	0.5	120
88	The riddle of the mast cell: kit(CD117)-ligand as the missing link?. Trends in Immunology, 1994, 15, 111-114.	7.5	117
89	Nonanaphylactic synthetic peptides derived from B cell epitopes of the major grass pollen allergen, Phl p 1, for allergy vaccination. FASEB Journal, 2001, 15, 2042-2044.	0.5	117
90	Prognostic factors for intensive care unit admission, intensive care outcome, and post-intensive care survival in patients with de novo acute myeloid leukemia: a single center experience. Haematologica, 2011, 96, 231-237.	3.5	116

#	Article	IF	Citations
91	Genetic engineering of a hypoallergenic trimer of the major birch pollen allergen, Bet v 1. FASEB Journal, 2001, 15, 2045-2047.	0.5	115
92	Development and characterization of a recombinant, hypoallergenic, peptide-based vaccine for grass pollen allergy. Journal of Allergy and Clinical Immunology, 2015, 135, 1207-1217.e11.	2.9	115
93	PDGFR blockade is a rational and effective therapy for NPM-ALKâ€“driven lymphomas. Nature Medicine, 2012, 18, 1699-1704.	30.7	113
94	Hereditary Î± tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis. Blood, 2021, 137, 238-247.	1.4	113
95	Pharmacologic inhibition of STAT5 in acute myeloid leukemia. Leukemia, 2018, 32, 1135-1146.	7.2	112
96	Diagnostic and Subdiagnostic Accumulation of Mast Cells in the Bone Marrow of Patients with Anaphylaxis: Monoclonal Mast Cell Activation Syndrome. International Archives of Allergy and Immunology, 2007, 142, 158-164.	2.1	111
97	Immunohistochemical properties of bone marrow mast cells in systemic mastocytosis: Evidence for expression of CD2, CD117/Kit, and bcl-xL. Human Pathology, 2001, 32, 545-552.	2.0	109
98	Mechanisms, safety and efficacy of a B cell epitope-based vaccine for immunotherapy of grass pollen allergy. EBioMedicine, 2016, 11, 43-57.	6.1	109
99	Constitutive activation of Stat5 promotes its cytoplasmic localization and association with PI3-kinase in myeloid leukemias. Blood, 2007, 109, 1678-1686.	1.4	108
100	The Mastocytosis Society Survey on Mast Cell Disorders: Patient Experiences and Perceptions. Journal of Allergy and Clinical Immunology: in Practice, 2014, 2, 70-76.	3.8	107
101	Mast cells as a unique hematopoietic lineage and cell system: From Paul Ehrlich's visions to precision medicine concepts. Theranostics, 2020, 10, 10743-10768.	10.0	107
102	How I treat patients with advanced systemic mastocytosis. Blood, 2010, 116, 5812-5817.	1.4	106
103	Calciumâ€dependent immunoglobulin E recognition of the apoâ€and calciumâ€bound form of a crossâ€reactive two EFâ€hand timothy grass pollen allergen, Phl p 7. FASEB Journal, 1999, 13, 843-856.	0.5	105
104	Further Characterization of Surface Membrane Structures Expressed on Human Basophils and Mast Cells. International Archives of Allergy and Immunology, 1990, 91, 198-203.	2.1	102
105	Clinical and Biologic Diversity of Leukemias Occurring in Patients with Mastocytosis. Leukemia and Lymphoma, 2000, 37, 473-486.	1.3	101
106	International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study. Lancet Haematology,the, 2019, 6, e638-e649.	4.6	101
107	Expression of the C5a receptor (CD88) on synovial mast cells in patients with rheumatoid arthritis. Arthritis and Rheumatism, 1998, 41, 233-245.	6.7	100
108	Symptomatic venous thromboembolism in acute leukemia. Incidence, risk factors, and impact on prognosis. Thrombosis Research, 2005, 115, 59-64.	1.7	99

#	Article	IF	Citations
109	Molecular characterization of dog albumin as a cross-reactive allergen. Journal of Allergy and Clinical Immunology, 1994, 93, 614-627.	2.9	98
110	Oncogenic Kit controls neoplastic mast cell growth through a Stat5/PI3-kinase signaling cascade. Blood, 2008, 112, 2463-2473.	1.4	97
111	Response and progression on midostaurin in advanced systemic mastocytosis: KIT D816V and other molecular markers. Blood, 2017, 130, 137-145.	1.4	97
112	Identification of common allergenic structures in mugwort and ragweed pollenâ˜†â˜†â˜†â˜…â˜…â˜…. Journal of Allergy and Clinical Immunology, 1998, 101, 196-206.	2.9	96
113	Systems-pharmacology dissection of a drug synergy in imatinib-resistant CML. Nature Chemical Biology, 2012, 8, 905-912.	8.0	96
114	Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6. Blood, 2016, 127, 2890-2902.	1.4	96
115	Der p 11 Is a Major Allergen for House Dust Mite-Allergic Patients Suffering from Atopic Dermatitis. Journal of Investigative Dermatology, 2015, 135, 102-109.	0.7	93
116	Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions. Haematologica, 2019, 104, 1935-1949.	3.5	93
117	Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT. Haematologica, 2007, 92, 1451-1459.	3.5	92
118	A hypoallergenic cat vaccine based on Fel d 1â€“derived peptides fused to hepatitis B PreS. Journal of Allergy and Clinical Immunology, 2011, 127, 1562-1570.e6.	2.9	92
119	Idiopathic cytopenia of undetermined significance (ICUS) versus low risk MDS: The diagnostic interface. Leukemia Research, 2007, 31, 1461-1468.	0.8	90
120	Chronic mast cell leukemia: A novel leukemia-variant with distinct morphological and clinical features. Leukemia Research, 2015, 39, 1-5.	0.8	90
121	Diagnostic Criteria and Classification of Mastocytosis in 2014. Immunology and Allergy Clinics of North America, 2014, 34, 207-218.	1.9	89
122	Adapting forest management to climate change in Europe: Linking perceptions to adaptive responses. Forest Policy and Economics, 2018, 90, 22-30.	3.4	87
123	Why the 20% + 2 Tryptase Formula Is a Diagnostic Gold Standard for Severe Systemic Mast Cell Activation and Mast Cell Activation Syndrome. International Archives of Allergy and Immunology, 2019, 180, 44-51.	2.1	87
124	Polo-like Kinase 1 (Plk1) as a Novel Drug Target in Chronic Myeloid Leukemia: Overriding Imatinib Resistance with the Plk1 Inhibitor BI 2536. Cancer Research, 2010, 70, 1513-1523.	0.9	86
125	Targeting of heat shock protein 32 (Hsp32)/heme oxygenase-1 (HO-1) in leukemic cells in chronic myeloid leukemia: a novel approach to overcome resistance against imatinib. Blood, 2008, 111, 2200-2210.	1.4	85
126	Phenotypic Characterization of Human Skin Mast Cells by Combined Staining with Toluidine Blue and CD Antibodies. Journal of Investigative Dermatology, 1998, 111, 689-695.	0.7	84

#	Article	IF	Citations
127	Hypoallergenic Der p 1/Der p 2 combination vaccines for immunotherapy of house dust mite allergy. Journal of Allergy and Clinical Immunology, 2012, 130, 435-443.e4.	2.9	84
128	The clinical and molecular diversity of mast cell leukemia with or without associated hematologic neoplasm. Haematologica, 2017, 102, 1035-1043.	3.5	84
129	A hybrid molecule resembling the epitope spectrum of grass pollen for allergy vaccination. Journal of Allergy and Clinical Immunology, 2005, 115, 1010-1016.	2.9	83
130	Idiopathic cytopenia of undetermined significance (ICUS) and idiopathic dysplasia of uncertain significance (IDUS), and their distinction from low risk MDS. Leukemia Research, 2011, 36, 1-5.	0.8	83
131	Mapping of Conformational IgE Epitopes with Peptide-Specific Monoclonal Antibodies Reveals Simultaneous Binding of Different IgE Antibodies to a Surface Patch on the Major Birch Pollen Allergen, Bet v 1. Journal of Immunology, 2011, 186, 5333-5344.	0.8	82
132	MARS: Mutation-Adjusted Risk Score for Advanced Systemic Mastocytosis. Journal of Clinical Oncology, 2019, 37, 2846-2856.	1.6	82
133	Diagnosis and treatment of autoimmune haemolytic anaemias in adults: a clinical review. Wiener Klinische Wochenschrift, 2008, 120, 136-151.	1.9	81
134	Molecular Aspects of Allergens and Allergy. Advances in Immunology, 2018, 138, 195-256.	2.2	81
135	Low-Level Expression of Proapoptotic Bcl-2â€“Interacting Mediator in Leukemic Cells in Patients with Chronic Myeloid Leukemia: Role of BCR/ABL, Characterization of Underlying Signaling Pathways, and Reexpression by Novel Pharmacologic Compounds. Cancer Research, 2005, 65, 9436-9444.	0.9	80
136	A Combination Vaccine for Allergy and Rhinovirus Infections Based on Rhinovirus-Derived Surface Protein VP1 and a Nonallergenic Peptide of the Major Timothy Grass Pollen Allergen Phl p 1. Journal of Immunology, 2009, 182, 6298-6306.	0.8	80
137	A new human mast cell line expressing a functional IgE receptor converts to tumorigenic growth by KIT D816V transfection. Blood, 2014, 124, 111-120.	1.4	80
138	Cancer stem cells in basic science and in translational oncology: can we translate into clinical application?. Journal of Hematology and Oncology, 2015, 8, 16.	17.0	80
139	Autoimmune thrombocytopenia in non-Hodgkin's lymphomas. Haematologica, 2008, 93, 447-450.	3.5	79
140	Antigens Drive Memory IgE Responses in Human Allergy via the Nasal Mucosa. International Archives of Allergy and Immunology, 2007, 142, 133-144.	2.1	78
141	The effects of dasatinib on IgE receptorâ€“dependent activation and histamine release in human basophils. Blood, 2008, 111, 3097-3107.	1.4	78
142	A Human Monoclonal IgE Antibody Defines a Highly Allergenic Fragment of the Major Timothy Grass Pollen Allergen, Phl p 5: Molecular, Immunological, and Structural Characterization of the Epitope-Containing Domain. Journal of Immunology, 2000, 165, 3849-3859.	0.8	77
143	Histopathological and Immunohistochemical Aspects of Mastocytosis. International Archives of Allergy and Immunology, 2002, 127, 115-117.	2.1	77
144	Indolent Systemic Mastocytosis with Elevated Serum Tryptase, Absence of Skin Lesions, and Recurrent Severe Anaphylactoid Episodes. International Archives of Allergy and Immunology, 2005, 136, 273-280.	2.1	77

#	Article	IF	Citations
145	Neoplastic stem cells: A novel therapeutic target in clinical oncology. Cancer, 2006, 107, 2512-2520.	4.1	77
146	Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders. Cancer Discovery, 2022, 12, 372-387.	9.4	77
147	The c-kit Ligand Stem Cell Factor and Anti-IgE Promote Expression of Monocyte Chemoattractant Protein-1 in Human Lung Mast Cells. Blood, 1997, 90, 4438-4449.	1.4	76
148	Amplification of the MLL gene on double minutes, a homogeneously staining region, and ring chromosomes in five patients with acute myeloid leukemia or myelodysplastic syndrome. Genes Chromosomes and Cancer, 2000, 27, 380-386.	2.8	76
149	Detection of Novel CD Antigens on the Surface of Human Mast Cells and Basophils. International Archives of Allergy and Immunology, 2002, 127, 299-307.	2.1	76
150	Mutants of the major ryegrass pollen allergen, Lol p 5, with reduced IgE-binding capacity: candidates for grass pollen-specific immunotherapy. European Journal of Immunology, 2002, 32, 270-280.	2.9	76
151	Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis. Biology of Blood and Marrow Transplantation, 2016, 22, 1348-1356.	2.0	76
152	Evaluation of Close-Range Photogrammetry Image Collection Methods for Estimating Tree Diameters. ISPRS International Journal of Geo-Information, 2018, 7, 93.	2.9	76
153	Unique Effects of KIT D816V in BaF3 Cells: Induction of Cluster Formation, Histamine Synthesis, and Early Mast Cell Differentiation Antigens. Journal of Immunology, 2008, 180, 5466-5476.	0.8	75
154	B cell epitopes of the major timothy grass pollen allergen, Phl p 1, revealed by gene fragmentation as candidates for immunotherapy. FASEB Journal, 1999, 13, 1277-1290.	0.5	73
155	Conversion of grass pollen allergen-specific human IgE into a protective IgG1 antibody. European Journal of Immunology, 2002, 32, 2156.	2.9	73
156	Hom s 4, an IgE-Reactive Autoantigen Belonging to a New Subfamily of Calcium-Binding Proteins, Can Induce Th Cell Type 1-Mediated Autoreactivity. Journal of Immunology, 2005, 175, 1286-1294.	0.8	73
157	Expression of Activated STAT5 in Neoplastic Mast Cells in Systemic Mastocytosis. American Journal of Pathology, 2009, 175, 2416-2429.	3.8	72
158	Formation of Disulfide Bonds and Homodimers of the Major Cat Allergen Fel d 1 Equivalent to the Natural Allergen by Expression in Escherichia coli. Journal of Biological Chemistry, 2003, 278, 40144-40151.	3.4	71
159	Pathogenesis, classification, and therapy of eosinophilia and eosinophil disorders. Blood Reviews, 2009, 23, 157-165.	5.7	71
160	ICUS, IDUS, CHIP and CCUS: Diagnostic Criteria, Separation from MDS and Clinical Implications. Pathobiology, 2019, 86, 30-38.	3.8	71
161	Spectrum of Associated Clonal Hematologic Non-Mast Cell Lineage Disorders Occurring in Patients with Systemic Mastocytosis. International Archives of Allergy and Immunology, 2002, 127, 140-142.	2.1	70
162	Conversion of Der p 23, a New Major House Dust Mite Allergen, into a Hypoallergenic Vaccine. Journal of Immunology, 2014, 192, 4867-4875.	0.8	69

#	Article	IF	Citations
163	Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor Cells. Cell Reports, 2018, 23, 3127-3136.	6.4	68
164	Myelomastocytic overlap syndromes: biology, criteria, and relationship to mastocytosis. Leukemia Research, 2001, 25, 595-602.	0.8	67
165	Characterization of123I-vascular endothelial growth factor-binding sites expressed on human tumour cells: Possible implication for tumour scintigraphy. International Journal of Cancer, 2001, 91, 789-796.	5.1	66
166	Individual Hymenoptera Venom Compounds Induce Upregulation of the Basophil Activation Marker Ectonucleotide Pyrophosphatase/Phosphodiesterase 3 (CD203c) in Sensitized Patients. International Archives of Allergy and Immunology, 2002, 129, 160-168.	2.1	66
167	Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group. Leukemia and Lymphoma, 2013, 54, 472-475.	1.3	66
168	The serum tryptase test: an emerging robust biomarker in clinical hematology. Expert Review of Hematology, 2014, 7, 683-690.	2.2	65
169	Characterization of Human Prostate Mast Cells and Their Increase in Periprostatic Vein Thrombosis. American Journal of Clinical Pathology, 2001, 116, 97-106.	0.7	64
170	Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis: inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC412. Blood, 2007, 109, 3031-3041.	1.4	64
171	Systemic Mastocytosis Associated with Chronic Idiopathic Myelofibrosis. Journal of Molecular Diagnostics, 2008, 10, 58-66.	2.8	64
172	KIT-D816Vâ€“independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib. Blood, 2011, 118, 1885-1898.	1.4	64
173	Aberrant expression of CD30 in aggressive systemic mastocytosis and mast cell leukemia: a differential diagnosis to consider in aggressive hematopoietic CD30-positive neoplasms. Leukemia and Lymphoma, 2011, 52, 740-744.	1.3	64
174	STAT5 triggersBCR-ABL1mutation by mediating ROS production in chronic myeloid leukaemia. Oncotarget, 2012, 3, 1669-1687.	1.8	64
175	Current treatment options in patients with mastocytosis: status in 2015 and future perspectives. European Journal of Haematology, 2015, 94, 474-490.	2.2	64
176	Multidisciplinary Challenges in Mastocytosis and How to Address with Personalized Medicine Approaches. International Journal of Molecular Sciences, 2019, 20, 2976.	4.1	64
177	Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cells. Journal of Clinical Investigation, 2017, 127, 2392-2406.	8.2	64
178	Hymenoptera-Venom-Induced Upregulation of the Basophil Activation Marker Ecto-Nucleotide Pyrophosphatase/Phosphodiesterase 3 in Sensitized Individuals. International Archives of Allergy and Immunology, 2001, 126, 335-342.	2.1	63
179	Generation of an Allergy Vaccine by Disruption of the Three-Dimensional Structure of the Cross-Reactive Calcium-Binding Allergen, Phl p 7. Journal of Immunology, 2004, 172, 5684-5692.	0.8	62
180	Delineation of target expression profiles in CD34+/CD38â^' and CD34+/CD38+ stem and progenitor cells in AML and CML. Blood Advances, 2020, 4, 5118-5132.	5.2	62

#	Article	IF	Citations
181	Smouldering Mastocytosis: A Novel Subtype of Systemic Mastocytosis with Slow Progression. International Archives of Allergy and Immunology, 2002, 127, 137-139.	2.1	61
182	Detection of c-kit point mutation Asp-816 â†' Val in microdissected pooled single mast cells and leukemic cells in a patient with systemic mastocytosis and concomitant chronic myelomonocytic leukemia. Leukemia Research, 2002, 26, 979-984.	0.8	61
183	Spatial clustering of the IgE epitopes on the major timothy grass pollen allergen Phl p 1: Importance for allergenic activity. Journal of Allergy and Clinical Immunology, 2006, 117, 1336-1343.	2.9	61
184	Large maculopapular cutaneous lesions are associated with favorable outcome in childhood-onset mastocytosis. Journal of Allergy and Clinical Immunology, 2015, 136, 1581-1590.e3.	2.9	61
185	Severe Life-Threatening or Disabling Anaphylaxis in Patients with Systemic Mastocytosis: A Single-Center Experience. International Archives of Allergy and Immunology, 2012, 157, 399-405.	2.1	60
186	Fatty acid synthase is a metabolic marker of cell proliferation rather than malignancy in ovarian cancer and its precursor cells. International Journal of Cancer, 2015, 136, 2078-2090.	5.1	60
187	Advanced systemic mastocytosis: from molecular and genetic progress to clinical practice. Haematologica, 2016, 101, 1133-1143.	3.5	60
188	Mast cell proliferative disorders: current view on variants recognized by the World Health Organization. Hematology/Oncology Clinics of North America, 2003, 17, 1227-1241.	2.2	59
189	CD34+/CD38- stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumab/ozogamicin. Haematologica, 2012, 97, 219-226.	3.5	59
190	Azacitidine in CMML: Matched-pair analyses of daily-life patients reveal modest effects on clinical course and survival. Leukemia Research, 2014, 38, 475-483.	0.8	59
191	First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia. Blood, 2017, 130, 2499-2503.	1.4	59
192	The phenotype of human eosinophils, basophils, and mast cells. Journal of Allergy and Clinical Immunology, 1994, 94, 1177-1183.	2.9	58
193	Detection of tryptase in cytoplasmic granules of basophils in patients with chronic myeloid leukemia and other myeloid neoplasms. Blood, 2001, 98, 2580-2583.	1.4	58
194	Risk factors and mechanisms contributing to TKI-induced vascular events in patients with CML. Leukemia Research, 2017, 59, 47-54.	0.8	58
195	Emerging stem cell concepts for imatinibâ€resistant chronic myeloid leukaemia: implications for the biology, management, and therapy of the disease. British Journal of Haematology, 2008, 142, 361-378.	2.5	57
196	Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs. Blood, 2009, 114, 5342-5351.	1.4	57
197	A Nonallergenic Birch Pollen Allergy Vaccine Consisting of Hepatitis PreSâ€"Fused Bet v 1 Peptides Focuses Blocking IgG toward IgE Epitopes and Shifts Immune Responses to a Tolerogenic and Th1 Phenotype. Journal of Immunology, 2013, 190, 3068-3078.	0.8	57
198	STAT5BN642H is a driver mutation for T cell neoplasia. Journal of Clinical Investigation, 2017, 128, 387-401.	8.2	57

#	Article	IF	Citations
199	Identification of mTOR as a novel bifunctional target in chronic myeloid leukemia: dissection of growthâ€inhibitory and VEGFâ€suppressive effects of rapamycin in leukemic cells. FASEB Journal, 2005, 19, 960-962.	0.5	56
200	Stat5a serine 725 and 779 phosphorylation is a prerequisite for hematopoietic transformation. Blood, 2010, 116, 1548-1558.	1.4	56
201	Diagnosis, Classification and Management of Mast Cell Activation Syndromes (MCAS) in the Era of Personalized Medicine. International Journal of Molecular Sciences, 2020, 21, 9030.	4.1	56
202	Expression and prognostic significance of different mRNA 5â€²â€end variants of the oncogene EVI1 in 266 patients with de novo AML: EVI1 and MDS1/EVI1 overexpression both predict short remission duration. Genes Chromosomes and Cancer, 2008, 47, 288-298.	2.8	55
203	Heterogeneity of Neoplastic Stem Cells: Theoretical, Functional, and Clinical Implications. Cancer Research, 2013, 73, 1037-1045.	0.9	55
204	The myeloma stem cell concept, revisited: from phenomenology to operational terms. Haematologica, 2016, 101, 1451-1459.	3.5	55
205	Myelomastocytic Leukemia: Evidence for the Origin of Mast Cells from the Leukemic Clone and Eradication by Allogeneic Stem Cell Transplantation. Clinical Cancer Research, 2005, 11, 6787-6792.	7.0	54
206	Tyrosine kinase inhibitorâ€“induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors. Blood, 2018, 132, 67-77.	1.4	54
207	Myelomastocytic leukemia: myeloid neoplasm characterized by partial differentiation of mast cell-lineage cells. The Hematology Journal, 2002, 3, 90-94.	1.4	54
208	Reduction of the in vivo allergenicity of Der p 2, the major house-dust mite allergen, by genetic engineering. Molecular Immunology, 2008, 45, 2486-2498.	2.2	53
209	Phenotypic heterogeneity, novel diagnostic markers, and target expression profiles in normal and neoplastic human mast cells. Best Practice and Research in Clinical Haematology, 2010, 23, 369-378.	1.7	53
210	Tumor necrosis factor Î± promotes the expression of stem cell factor in synovial fibroblasts and their capacity to induce mast cell chemotaxis. Arthritis and Rheumatism, 2000, 43, 164-174.	6.7	52
211	Morphologic and Immunophenotypic Properties of Neoplastic Cells in a Case of Mast Cell Sarcoma. American Journal of Surgical Pathology, 2003, 27, 1013-1019.	3.7	52
212	Evaluation of the prognostic significance of Eosinophilia and Basophilia in a larger cohort of patients with myelodysplastic syndromes. Cancer, 2010, 116, 2372-2381.	4.1	52
213	The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells. Breast Cancer Research and Treatment, 2011, 129, 387-400.	2.5	52
214	Targeting of Leukemia-Initiating Cells to Develop Curative Drug Therapies: Straightforward but Nontrivial Concept. Current Cancer Drug Targets, 2011, 11, 56-71.	1.6	52
215	Identification of CD25 as STAT5-Dependent Growth Regulator of Leukemic Stem Cells in Ph+ CML. Clinical Cancer Research, 2016, 22, 2051-2061.	7.0	52
216	Standards and Impact of Hematopathology in Myelodysplastic Syndromes (MDS). Oncotarget, 2010, 1, 483-496.	1.8	52

#	Article	IF	Citations
217	Purification of human basophils and mast cells by multistep separation technique and mAb to CDw17 and. Journal of Immunological Methods, 1995, 182, 115-129.	1.4	51
218	Extensive pleural and pericardial effusion in chronic myeloid leukemia during treatment with dasatinib at 100 mg or 50 mg daily. Haematologica, 2011, 96, 163-166.	3.5	51
219	DPPIV (CD26) as a novel stem cell marker in Ph+ chronic myeloid leukaemia. European Journal of Clinical Investigation, 2014, 44, 1239-1245.	3.4	51
220	Molecular Characterization of Polygalacturonases as Grass Pollen-Specific Marker Allergens: Expulsion from Pollen via Submicronic Respirable Particles. Journal of Immunology, 2004, 172, 6490-6500.	0.8	50
221	Identification of Basogranulin (BB1) as a Novel Immunohistochemical Marker of Basophils in Normal Bone Marrow and Patients With Myeloproliferative Disorders. American Journal of Clinical Pathology, 2006, 125, 273-281.	0.7	50
222	Synergistic antiproliferative effects of KIT tyrosine kinase inhibitors on neoplastic canine mast cells. Experimental Hematology, 2007, 35, 1510-1521.	0.4	50
223	Myelomastocytic leukemia versus mast cell leukemia versus systemic mastocytosis associated with acute myeloid leukemia: A diagnostic challenge. American Journal of Hematology, 2010, 85, 600-606.	4.1	50
224	Developmental, Malignancy-Related, and Cross-Species Analysis of Eosinophil, Mast Cell, and Basophil Siglec-8 Expression. Journal of Clinical Immunology, 2011, 31, 1045-1053.	3.8	50
225	Co-operating STAT5 and AKT signaling pathways in chronic myeloid leukemia and mastocytosis: possible new targets of therapy. Haematologica, 2014, 99, 417-429.	3.5	50
226	Clonal Hematopoiesis with Oncogenic Potential (CHOP): Separation from CHIP and Roads to AML. International Journal of Molecular Sciences, 2019, 20, 789.	4.1	50
227	Long-term treatment with imatinib results in profound mast cell deficiency in Ph+ chronic myeloid leukemia. Oncotarget, 2015, 6, 3071-3084.	1.8	50
228	New Aspects in Thrombotic Research: Complement Induced Switch in Mast Cells from a Profibrinolytic to a Prothrombotic Phenotype. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2003, 33, 438-441.	0.3	49
229	Diagnostic value of histology and immunohistochemistry in myelodysplastic syndromes. Leukemia Research, 2007, 31, 1609-1616.	0.8	49
230	Digital PCR: A Sensitive and Precise Method for KIT D816V Quantification in Mastocytosis. Clinical Chemistry, 2018, 64, 547-555.	3.2	49
231	Normal and pathological erythropoiesis in adults: from gene regulation to targeted treatment concepts. Haematologica, 2018, 103, 1593-1603.	3.5	49
232	The human basophil. Critical Reviews in Oncology/Hematology, 1990, 10, 327-352.	4.4	48
233	Expression, epitope analysis, and functional role of the LFA-2 antigen detectable on neoplastic mast cells. Blood, 2001, 98, 3784-3792.	1.4	48
234	The IgE-Reactive Autoantigen Hom s 2 Induces Damage of Respiratory Epithelial Cells and Keratinocytes via Induction of IFN-Î³. Journal of Investigative Dermatology, 2008, 128, 1451-1459.	0.7	48

#	Article	IF	Citations
235	Leukemic challenge unmasks a requirement for PI3KÎ´ in NK cellâ€“mediated tumor surveillance. Blood, 2008, 112, 4655-4664.	1.4	48
236	Incidence and prognostic impact of cytogenetic aberrations in patients with systemic mastocytosis. Genes Chromosomes and Cancer, 2018, 57, 252-259.	2.8	48
237	Detection of vascular endothelial growth factor (VEGF) and VEGF receptors Flt-1 and KDR in canine mastocytoma cells. Veterinary Immunology and Immunopathology, 2007, 115, 320-333.	1.2	47
238	Identification of the Ki-1 antigen (CD30) as a novel therapeutic target in systemic mastocytosis. Blood, 2015, 126, 2832-2841.	1.4	47
239	Novel Targeted Therapies for Eosinophil-Associated Diseases and Allergy. Annual Review of Pharmacology and Toxicology, 2015, 55, 633-656.	9.4	47
240	Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classification. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 1927-1938.	5.7	47
241	Increase and Redistribution of Cardiac Mast Cells in Auricular Thrombosis. Circulation, 1995, 91, 275-283.	1.6	47
242	Delineation of Patterns of Bone Marrow Mast Cell Infiltration in Systemic Mastocytosis. American Journal of Clinical Pathology, 2005, 124, 560-568.	0.7	46
243	Diagnostic Evaluation and Classification of Mastocytosis. Immunology and Allergy Clinics of North America, 2006, 26, 515-534.	1.9	46
244	Vaccination with genetically modified birch pollen allergens: Immune and clinical effects on oral allergy syndrome. Journal of Allergy and Clinical Immunology, 2007, 119, 1013-1016.	2.9	46
245	In vitro and in vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816V. Experimental Hematology, 2010, 38, 744-755.	0.4	46
246	Clinical and Laboratory Parameters of Mast Cell Activation as Basis for the Formulation of Diagnostic Criteria. International Archives of Allergy and Immunology, 2011, 156, 119-127.	2.1	46
247	Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes. Blood, 2016, 128, 2096-2097.	1.4	46
248	CDK6 is an essential direct target of NUP98 fusion proteins in acute myeloid leukemia. Blood, 2020, 136, 387-400.	1.4	46
249	Increased Angiogenesis in the Bone Marrow of Patients with Systemic Mastocytosis. American Journal of Pathology, 2002, 160, 1639-1645.	3.8	45
250	Characterization of Wild-Type Recombinant Bet v 1a as a Candidate Vaccine against Birch Pollen Allergy. International Archives of Allergy and Immunology, 2005, 136, 239-249.	2.1	45
251	Identification of Basophils as a Major Source of Hepatocyte Growth Factor in Chronic Myeloid Leukemia: A Novel Mechanism of BCR-ABL1-Independent Disease Progression. Neoplasia, 2012, 14, 572-IN10.	5.3	45
252	Overexpression of primary microRNA 221/222 in acute myeloid leukemia. BMC Cancer, 2013, 13, 364.	2.6	45

#	Article	IF	Citations
253	The growth and differentiation of mast cells. Progress in Growth Factor Research, 1991, 3, 27-41.	1.6	44
254	Inhibition of Stem Cell Factor Dependent Formation of Human Mast Cells by Interleukin-3 and Interleukin-4. International Archives of Allergy and Immunology, 1994, 105, 264-268.	2.1	44
255	Effects of cyclosporin A and FK-506 on stem cell factorâ€“induced histamine secretion and growth of human mast cells. Journal of Allergy and Clinical Immunology, 1996, 98, 389-399.	2.9	44
256	Overexpression of complement receptors and related antigens on the surface of bone marrow mast cells in patients with systemic mastocytosis. British Journal of Haematology, 2003, 120, 257-265.	2.5	44
257	High frequency of concomitant mastocytosis in patients with acute myeloid leukemia exhibiting the transforming KIT mutation D816V. Molecular Oncology, 2010, 4, 335-346.	4.6	44
258	Familial hypertryptasemia with associated mast cell activation syndrome. Journal of Allergy and Clinical Immunology, 2014, 134, 1448-1450.e3.	2.9	44
259	Immunotherapy-Based Targeting and Elimination of Leukemic Stem Cells in AML and CML. International Journal of Molecular Sciences, 2019, 20, 4233.	4.1	44
260	RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis. Nature Communications, 2021, 12, 2901.	12.8	44
261	Induction of IgE antibodies with predefined specificity in rhesus monkeys with recombinant birch pollen allergens, Bet v 1 and Bet v 2. Journal of Allergy and Clinical Immunology, 1996, 97, 95-103.	2.9	43
262	A case of â€˜smoulderingâ€™ mastocytosis with high mast cell burden, monoclonal myeloid cells, and C-KIT mutation Asp-816-Val. Leukemia Research, 2001, 25, 627-634.	0.8	43
263	Assays for measuring in vitro basophil activation induced by recombinant allergens. Methods, 2004, 32, 265-270.	3.8	43
264	Identification of heat shock protein 32 (Hsp32) as a novel survival factor and therapeutic target in neoplastic mast cells. Blood, 2007, 110, 661-669.	1.4	43
265	Mast cellâ€“derived proteases control allergic inflammation through cleavage of IgE. Journal of Allergy and Clinical Immunology, 2008, 121, 197-202.	2.9	43
266	Characterization of Folded Recombinant Der p 5, a Potential Diagnostic Marker Allergen for House Dust Mite Allergy. International Archives of Allergy and Immunology, 2008, 147, 101-109.	2.1	43
267	MLL-fusion-driven leukemia requires SETD2 to safeguard genomic integrity. Nature Communications, 2018, 9, 1983.	12.8	43
268	Multi-level suppression of receptor-PI3K-mTORC1 by fatty acid synthase inhibitors is crucial for their efficacy against ovarian cancer cells. Oncotarget, 2017, 8, 11600-11613.	1.8	43
269	Tryptase a Novel Biochemical Marker of Acute Myeloid Leukemia. Leukemia and Lymphoma, 2002, 43, 2257-2261.	1.3	42
270	In Human Macrophages the Complement Component C5a Induces the Expression of Oncostatin M via AP-1 Activation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, 498-503.	2.4	42

#	Article	IF	Citations
271	Low blood counts: immune mediated, idiopathic, or myelodysplasia. Hematology American Society of Hematology Education Program, 2012, 2012, 485-491.	2.5	42
272	The Data Registry of the European Competence Network on Mastocytosis (ECNM): Set Up, Projects, and Perspectives. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 81-87.	3.8	42
273	Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis. Journal of Allergy and Clinical Immunology, 2020, 146, 356-366.e4.	2.9	42
274	Mast Cell-Lineage Versus Basophil Lineage Involvement in Myeloproliferative and Myelodysplastic Syndromes: Diagnostic Role of Cell-Immunopheno typing. Leukemia and Lymphoma, 1996, 22, 187-204.	1.3	41
275	Immunohistochemical detection of vascular endothelial growth factor (VEGF) in the bone marrow in patients with myelodysplastic syndromes: correlation between VEGF expression and the FAB category. Leukemia and Lymphoma, 2006, 47, 451-460.	1.3	41
276	5-azacytidine and decitabine exert proapoptotic effects on neoplastic mast cells: role of FAS-demethylation and FAS re-expression, and synergism with FAS-ligand. Blood, 2012, 119, 4242-4252.	1.4	41
277	Identification of Ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFRA. Experimental Hematology, 2014, 42, 282-293.e4.	0.4	41
278	Nilotinib Exerts Direct Pro-Atherogenic and Anti-Angiogenic Effects On Vascular Endothelial Cells: A Potential Explanation For Drug-Induced Vasculopathy In CML. Blood, 2013, 122, 257-257.	1.4	41
279	Evaluation of Angiogenesis and Vascular Endothelial Growth Factor Expression in the Bone Marrow of Patients with Aplastic Anemia. American Journal of Pathology, 2006, 168, 123-130.	3.8	40
280	Hypoallergenic derivatives of the major birch pollen allergen Bet v 1 obtained by rational sequence reassembly. Journal of Allergy and Clinical Immunology, 2010, 126, 1024-1031.e8.	2.9	40
281	Identification of oncostatin M as a JAK2 V617Fâ€dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms. FASEB Journal, 2012, 26, 894-906.	0.5	40
282	Cytokine Regulation of Microenvironmental Cells in Myeloproliferative Neoplasms. Mediators of Inflammation, 2015, 2015, 1-17.	3.0	40
283	Twins with different personalities: STAT5Bâ€”but not STAT5Aâ€”has a key role in BCR/ABL-induced leukemia. Leukemia, 2019, 33, 1583-1597.	7.2	40
284	What Have Mast Cells To Do with Edema Formation, the Consecutive Repair and Fibrinolysis?. International Archives of Allergy and Immunology, 1998, 115, 2-8.	2.1	39
285	Myeloid leukemias express a broad spectrum of VEGF receptors including neuropilin-1 (NRP-1) and NRP-2. Leukemia and Lymphoma, 2007, 48, 1997-2007.	1.3	39
286	Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: the ENESTnd study. Expert Review of Hematology, 2010, 3, 665-673.	2.2	39
287	Synergistic growth-inhibitory effects of ponatinib and midostaurin (PKC412) on neoplastic mast cells carrying KIT D816V. Haematologica, 2013, 98, 1450-1457.	3.5	39
288	Diagnosis and management of mastocytosis: an emerging challenge in applied hematology. Hematology American Society of Hematology Education Program, 2015, 2015, 98-105.	2.5	39

#	Article	IF	Citations
289	Mast Cells, Mastocytosis, and Related Disorders. New England Journal of Medicine, 2015, 373, 1884-1886.	27.0	39
290	Mesenchymal Stem and Progenitor Cells in Normal and Dysplastic Hematopoiesisâ€"Masters of Survival and Clonality?. International Journal of Molecular Sciences, 2016, 17, 1009.	4.1	39
291	Proposed global prognostic score for systemic mastocytosis: a retrospective prognostic modelling study. Lancet Haematology,the, 2021, 8, e194-e204.	4.6	39
292	Inhibition of STAT5: A therapeutic option in BCR-ABL1-driven leukemia. Oncotarget, 2014, 5, 9564-9576.	1.8	39
293	Cytokines involved in growth and differentiation of human basophils and mast cells. Experimental Dermatology, 1995, 4, 255-259.	2.9	38
294	Amplification of the AML1(CBFA2) gene on ring chromosomes in a patient with acute myeloid leukemia and a constitutional ring chromosome 21. Cancer Genetics and Cytogenetics, 2001, 124, 42-46.	1.0	38
295	Prognostic value of lactate dehydrogenase activity in myelodysplastic syndromes. Leukemia Research, 2001, 25, 287-294.	0.8	38
296	IFN-Î³â€"enhanced allergen penetration across respiratory epithelium augments allergic inflammation. Journal of Allergy and Clinical Immunology, 2005, 115, 973-981.	2.9	38
297	Second line BCR/ABK TKI-associated severe adverse events:preferential occurrence in patients with comorbidities. Haematologica, 2011, 96, 1395-7.	3.5	38
298	Molecular Background, Clinical Features and Management of Pediatric Mastocytosis: Status 2021. International Journal of Molecular Sciences, 2021, 22, 2586.	4.1	38
299	Systemic mastocytosis (SM) associated with chronic eosinophilic leukemia (SM-CEL): Detection of FIP1L1/PDGFRÎ±, classification by WHO criteria, and response to therapy with imatinib. Leukemia Research, 2006, 30, 1201-1205.	0.8	37
300	Impact of Age and Comorbidity in Myelodysplastic Syndromes. Journal of the National Comprehensive Cancer Network: JNCCN, 2008, 6, 927-934.	4.9	37
301	Diagnosis, progression patterns and prognostication in mastocytosis. Expert Review of Hematology, 2012, 5, 261-274.	2.2	37
302	Frequent occurrence of TÂcellâ€"mediated late reactions revealed by atopy patch testing with hypoallergenic rBet v 1 fragments. Journal of Allergy and Clinical Immunology, 2016, 137, 601-609.e8.	2.9	37
303	Identification of Oncostatin M as a STAT5-Dependent Mediator of Bone Marrow Remodeling in KIT D816V-Positive Systemic Mastocytosis. American Journal of Pathology, 2011, 178, 2344-2356.	3.8	36
304	A randomized, openâ€label, phase I/II trial to investigate the maximum tolerated dose of the <scp>P</scp>oloâ€like kinase inhibitor <scp>BI</scp> 2536 in elderly patients with refractory/relapsed acute myeloid leukaemia. British Journal of Haematology, 2013, 163, 214-222.	2.5	36
305	Dissection of the IgE and T-cell recognition of the major group 5 grass pollen allergen Phl p 5. Journal of Allergy and Clinical Immunology, 2014, 133, 836-845.e11.	2.9	36
306	Reduced CD62L Expression on T Cells and Increased Soluble CD62L Levels Predict Molecular Response to Tyrosine Kinase Inhibitor Therapy in Early Chronic-Phase Chronic Myelogenous Leukemia. Journal of Clinical Oncology, 2017, 35, 175-184.	1.6	36

#	Article	IF	Citations
307	Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia. Haematologica, 2017, 102, 1519-1529.	3.5	36
308	Immunohistochemical Detection of VEGF in the Bone Marrow of Patients With Acute Myeloid Leukemia. American Journal of Clinical Pathology, 2003, 119, 663-671.	0.7	35
309	H1-receptor antagonists terfenadine and loratadine inhibit spontaneous growth of neoplastic mast cells. Experimental Hematology, 2010, 38, 896-907.	0.4	35
310	Targeting of VEGFâ€dependent transendothelial migration of cancer cells by bevacizumab. Molecular Oncology, 2010, 4, 150-160.	4.6	35
311	Personalized Management Strategies in Mast Cell Disorders: ECNM-AIM Userâ€™s Guide for Daily Clinical Practice. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 1999-2012.e6.	3.8	35
312	Chronic Myelogenous Leukemia and Myeloproliferative Disease. Hematology American Society of Hematology Education Program, 2004, 2004, 146-162.	2.5	34
313	Effects of the CD33-targeted drug gemtuzumab ozogamicin (Mylotarg) on growth and mediator secretion in human mast cells and blood basophils. Experimental Hematology, 2007, 35, 108-116.	0.4	34
314	Gliotoxin is a potent <scp>NOTCH</scp>2 transactivation inhibitor and efficiently induces apoptosis in chronic lymphocytic leukaemia (<scp>CLL</scp>) cells. British Journal of Haematology, 2013, 160, 618-629.	2.5	34
315	High Precision Individual Tree Diameter and Perimeter Estimation from Close-Range Photogrammetry. Forests, 2018, 9, 696.	2.1	34
316	Doctor, I Think I Am Suffering from MCAS: Differential Diagnosis and Separating Facts from Fiction. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 1109-1114.	3.8	34
317	Prognostic impact of eosinophils in mastocytosis: analysis of 2350 patients collected in the ECNM Registry. Leukemia, 2020, 34, 1090-1101.	7.2	34
318	Mastocytosis â€“ A Disease of the Hematopoietic Stem Cell. Deutsches Ärzteblatt International, 2008, 105, 686-92.	0.9	34
319	Altered IgE epitope presentation: A model for hypoallergenic activity revealed for Bet v 1 trimer. Molecular Immunology, 2011, 48, 431-441.	2.2	33
320	European Competence Network on Mastocytosis (ECNM): 10-year jubilee, update, and future perspectives. Wiener Klinische Wochenschrift, 2012, 124, 807-814.	1.9	33
321	A kinase-independent role for CDK8 in BCR-ABL1+ leukemia. Nature Communications, 2019, 10, 4741.	12.8	33
322	Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 3918-3928.	3.8	33
323	Genetic Engineering of Recombinant Hypoallergenic Oligomers of the Major Birch Pollen Allergen, Bet v 1: Candidates for Specific Immunotherapy. International Archives of Allergy and Immunology, 1999, 118, 218-219.	2.1	32
324	A case of smouldering mastocytosis with peripheral blood eosinophilia and lymphadenopathy. Leukemia Research, 2002, 26, 601-606.	0.8	32

#	Article	IF	Citations
325	Gain of structure and IgE epitopes by eukaryotic expression of the major Timothy grass pollen allergen, Phlâ€ƒpâ€ƒ1. FEBS Journal, 2005, 272, 217-227.	4.7	32
326	The pan-Bcl-2 blocker obatoclax promotes the expression of Puma, Noxa, and Bim mRNA and induces apoptosis in neoplastic mast cells. Journal of Leukocyte Biology, 2013, 95, 95-104.	3.3	32
327	Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases. Blood, 2016, 127, 2131-2143.	1.4	32
328	Phenotyping and Target Expression Profiling of CD34+/CD38â^' and CD34+/CD38+ Stem- and Progenitor cells in Acute Lymphoblastic Leukemia. Neoplasia, 2018, 20, 632-642.	5.3	32
329	A hypoallergenic peptide mix containing T cell epitopes of the clinically relevant house dust mite allergens. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 2461-2478.	5.7	32
330	Massive release of the histamineâ€degrading enzyme diamine oxidase during severe anaphylaxis in mastocytosis patients. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 583-593.	5.7	32
331	Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort study. Lancet Haematology,the, 2021, 8, e135-e148.	4.6	32
332	Eosinophils and eosinophil-associated disorders: immunological, clinical, and molecular complexity. Seminars in Immunopathology, 2021, 43, 423-438.	6.1	32
333	JAKâ€STAT core cancer pathway: An integrative cancer interactome analysis. Journal of Cellular and Molecular Medicine, 2022, 26, 2049-2062.	3.6	32
334	In vitro and in vivo studies of three radiolabelled somatostatin analogues:123I-Octreotide (OCT),123I-Tyr-3-OCT and111In-TIRA-d-Phe-1-OCT. European Journal of Nuclear Medicine and Molecular Imaging, 1996, 23, 1388-1399.	2.1	31
335	Bone Marrow Microvessel Density and it's Prognostic Significance in AML. Leukemia and Lymphoma, 2004, 45, 1369-1373.	1.3	31
336	Expression of CD25 on leukemic stem cells in BCR-ABL1+ CML: Potential diagnostic value and functional implications. Experimental Hematology, 2017, 51, 17-24.	0.4	31
337	COVID-19 Vaccination in Mastocytosis: Recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM). Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 2139-2144.	3.8	31
338	Quantitative assessment of the CD26+ leukemic stem cell compartment in chronic myeloid leukemia: patient-subgroups, prognostic impact, and technical aspects. Oncotarget, 2016, 7, 33016-33024.	1.8	31
339	Immunohistochemical Detection of VEGF in the Bone Marrow of Patients With Chronic Myeloid Leukemia and Correlation With the Phase of Disease. American Journal of Clinical Pathology, 2004, 121, 473-481.	0.7	30
340	Eosinophilia in systemic mastocytosis: Clinical and molecular correlates and prognostic significance. Journal of Allergy and Clinical Immunology, 2007, 120, 192-199.	2.9	30
341	Comparison of a Treatment Strategy Combining CCI-779 Plus DTIC Versus DTIC Monotreatment in Human Melanoma in SCID Mice. Journal of Investigative Dermatology, 2007, 127, 2411-2417.	0.7	30
342	Mastocytosis. Immunology and Allergy Clinics of North America, 2014, 34, 315-321.	1.9	30

#	Article	IF	Citations
343	Molecular, Structural and Immunological Characterization of Der p 18, a Chitinase-Like House Dust Mite Allergen. PLoS ONE, 2016, 11, e0160641.	2.5	30
344	The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis. Haematologica, 2018, 103, 799-809.	3.5	30
345	Characterization of IgEâ€“Reactive Autoantigens in Atopic Dermatitis 1. Subcellular Distribution and Tissueâ€“Specific Expression. International Archives of Allergy and Immunology, 1999, 120, 108-116.	2.1	29
346	Activation of Human Mast Cells through Stem Cell Factor Receptor (KIT) Is Associated with Expression of bcl-2. International Archives of Allergy and Immunology, 2002, 129, 228-236.	2.1	29
347	Chronic myeloid leukemia: Pathophysiology, diagnostic parameters, and current treatment concepts. Wiener Klinische Wochenschrift, 2003, 115, 485-504.	1.9	29
348	Aleukemic Mast Cell Leukemia with Abnormal Immunophenotype and C-kit Mutation D816V. Leukemia and Lymphoma, 2004, 45, 2295-2302.	1.3	29
349	Bone Marrow Mastocytosis Associated with IgM Kappa Plasma Cell Myeloma. Leukemia and Lymphoma, 2004, 45, 801-805.	1.3	29
350	A hypoallergenic hybrid molecule with increased immunogenicity consisting of derivatives of the major grass pollen allergens, Phl p 2 and Phl p 6. Biological Chemistry, 2008, 389, 925-33.	2.5	29
351	Neoplastic stem cells: Current concepts and clinical perspectives. Critical Reviews in Oncology/Hematology, 2010, 76, 79-98.	4.4	29
352	Genetic engineering of trimers of hypoallergenic fragments of the major birch pollen allergen, Bet v 1, for allergy vaccination. Vaccine, 2011, 29, 2140-2148.	3.8	29
353	Quantification of human diamine oxidase. Clinical Biochemistry, 2017, 50, 444-451.	1.9	29
354	KIT D816 mutated/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis. Leukemia, 2019, 33, 1124-1134.	7.2	29
355	CDK6 coordinates JAK2V617F mutant MPN via NF-Î°B and apoptotic networks. Blood, 2019, 133, 1677-1690.	1.4	29
356	Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis. Leukemia, 2022, 36, 516-524.	7.2	29
357	The immunoglobulin-like modules CÎµ3 and Î±2 are the minimal units necessary for human IgE-FcÎµRI interaction. Journal of Clinical Investigation, 1999, 103, 1571-1578.	8.2	29
358	The Immunoglobulin Eâ€“Allergen Interaction: A Target for Therapy of Type IAllergic Diseases. International Archives of Allergy and Immunology, 1998, 116, 167-176.	2.1	28
359	Human erythroleukemia genetics and transcriptomes identify master transcription factors as functional disease drivers. Blood, 2020, 136, 698-714.	1.4	28
360	Importance of Adequate Diagnostic Workup for Correct Diagnosis of Advanced Systemic Mastocytosis. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 3121-3127.e1.	3.8	28

#	Article	IF	Citations
361	Standards and impact of hematopathology in myelodysplastic syndromes (MDS). Oncotarget, 2010, 1, 483-96.	1.8	28
362	KIT as a master regulator of the mast cell lineage. Journal of Allergy and Clinical Immunology, 2022, 149, 1845-1854.	2.9	28
363	Cerivastatin and atorvastatin inhibit IL-3-dependent differentiation and IgE-mediated histamine release in human basophils and downmodulate expression of the basophil-activation antigen CD203c/E-NPP3. Journal of Leukocyte Biology, 2003, 73, 107-117.	3.3	27
364	CD33 as a target of therapy in acute myeloid leukemia: current status and future perspectives. Leukemia and Lymphoma, 2005, 46, 1115-1120.	1.3	27
365	Urticaria pigmentosa and mastocytosis: The role of immunophenotyping in diagnosis and determining response to treatment. Current Allergy and Asthma Reports, 2006, 6, 282-288.	5.3	27
366	Genetic Engineering of the Major Timothy Grass Pollen Allergen, Phl p 6, to Reduce Allergenic Activity and Preserve Immunogenicity. Journal of Immunology, 2007, 179, 1730-1739.	0.8	27
367	A Hypoallergenic Vaccine Obtained by Tail-to-Head Restructuring of Timothy Grass Pollen Profilin, Phl p 12, for the Treatment of Cross-Sensitization to Profilin. Journal of Immunology, 2007, 179, 7624-7634.	0.8	27
368	The chemokine interleukinâ€8 and the surface activation protein CD69 are markers for Bcrâ€“Abl activity in chronic myeloid leukemia. Molecular Oncology, 2008, 2, 272-281.	4.6	27
369	NOTCH2 links protein kinase C delta to the expression of CD23 in chronic lymphocytic leukaemia (CLL) cells. British Journal of Haematology, 2010, 148, 868-878.	2.5	27
370	Mast cell activation syndrome: Importance of consensus criteria and call for research. Journal of Allergy and Clinical Immunology, 2018, 142, 1008-1010.	2.9	27
371	High activation of STAT5A drives peripheral T-cell lymphoma and leukemia. Haematologica, 2020, 105, 435-447.	3.5	27
372	Disruption of Allergenic Activity of the Major Grass Pollen Allergen Phl p 2 by Reassembly as a Mosaic Protein. Journal of Immunology, 2008, 181, 4864-4873.	0.8	26
373	Role of interleukins in the regulation of basophil development and secretion. Current Opinion in Hematology, 2010, 17, 60-66.	2.5	26
374	Identification of Campath-1 (CD52) as Novel Drug Target in Neoplastic Stem Cells in 5q-Patients with MDS and AML. Clinical Cancer Research, 2014, 20, 3589-3602.	7.0	26
375	BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib. Haematologica, 2018, 103, e10-e12.	3.5	26
376	Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis. Theranostics, 2021, 11, 292-303.	10.0	26
377	Low blood counts: immune mediated, idiopathic, or myelodysplasia. Hematology American Society of Hematology Education Program, 2012, 2012, 485-91.	2.5	26
378	Azacitidine in Patients with Acute Myeloid Leukemia: Impact of Intermediate-Risk Vs High-Risk Cytogenetics on Patient Outcomes. Blood, 2014, 124, 955-955.	1.4	26

#	Article	IF	Citations
379	Immunophenotypic and functional characterization of human tonsillar mast cells. Journal of Leukocyte Biology, 1997, 61, 592-599.	3.3	25
380	Mast cells are augmented in deep vein thrombosis and express a profibrinolytic phenotype. Human Pathology, 1999, 30, 188-194.	2.0	25
381	Transjugular intrahepatic portosystemic shunt for treatment of portal hypertension due to extramedullary hematopoiesis in idiopathic myelofibrosis. Blood, 2002, 99, 4246-4247.	1.4	25
382	A Novel Effective and Safe Consolidation for Patients Over 60 Years with Acute Myeloid Leukemia. Clinical Cancer Research, 2004, 10, 3965-3971.	7.0	25
383	Cell Surface Membrane Antigen Phenotype of Human Gastrointestinal Mast Cells. International Archives of Allergy and Immunology, 2005, 138, 111-120.	2.1	25
384	Allergen cleavage by effector cellâ€derived proteases regulates allergic inflammation. FASEB Journal, 2006, 20, 967-969.	0.5	25
385	ICON: Eosinophil Disorders. World Allergy Organization Journal, 2012, 5, 174-181.	3.5	25
386	BRD4: A BET(ter) target for the treatment of AML?. Cell Cycle, 2014, 13, 689-690.	2.6	25
387	Targeting the JAK2-STAT5 pathway in CML. Blood, 2014, 124, 1386-1388.	1.4	25
388	The underestimated role of basophils in Ph⁺ chronic myeloid leukaemia. European Journal of Clinical Investigation, 2018, 48, e13000.	3.4	25
389	Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21). Blood Advances, 2021, 5, 2481-2489.	5.2	25
390	TET2 and DNMT3A Mutations Exert Divergent Effects on DNA Repair and Sensitivity of Leukemia Cells to PARP Inhibitors. Cancer Research, 2021, 81, 5089-5101.	0.9	25
391	Stem Cell Factor-induced Bone Marrow Mast Cell Hyperplasia Mimicking Systemic Mastocytosis (SM): Histopathologic and Morphologic Evaluation with Special Reference to Recently Established SM-criteria. Leukemia and Lymphoma, 2002, 43, 575-582.	1.3	24
392	Dasatinib inhibits the growth and survival of neoplastic human eosinophils (EOL-1) through targeting of FIP1L1-PDGFRÎ±. Experimental Hematology, 2008, 36, 1244-1253.	0.4	24
393	Diagnostic and prognostic value of new biochemical and immunohistochemical parameters in chronic myeloid leukemia. Leukemia and Lymphoma, 2008, 49, 635-638.	1.3	24
394	Clustering of comorbidities is related to age and sex and impacts clinical outcome in myelodysplastic syndromes. Journal of Geriatric Oncology, 2014, 5, 299-306.	1.0	24
395	The role of epigenetics in the regulation of apoptosis in myelodysplastic syndromes and acute myeloid leukemia. Critical Reviews in Oncology/Hematology, 2014, 90, 1-16.	4.4	24
396	CD52 is a molecular target in advanced systemic mastocytosis. FASEB Journal, 2014, 28, 3540-3551.	0.5	24

#	Article	IF	Citations
397	CCL2 is a KIT D816Vâ€“dependent modulator of the bone marrow microenvironment in systemic mastocytosis. Blood, 2017, 129, 371-382.	1.4	24
398	Proposed Terminology and Classification of Pre-Malignant Neoplastic Conditions: A Consensus Proposal. EBioMedicine, 2017, 26, 17-24.	6.1	24
399	Thinning trainer based on forest-growth model, virtual reality and computer-aided virtual environment. Environmental Modelling and Software, 2018, 100, 11-23.	4.5	24
400	Thrombin Augments Vascular Cell-dependent Migration of Human Mast Cells: Role of MGF. Thrombosis and Haemostasis, 1997, 77, 577-584.	3.4	24
401	The PI3-Kinase/mTOR-Targeting Drug NVP-BEZ235 Inhibits Growth and IgE-Dependent Activation of Human Mast Cells and Basophils. PLoS ONE, 2012, 7, e29925.	2.5	24
402	Superior Efficacy of Midostaurin Over Cladribine in Advanced Systemic Mastocytosis: A Registry-Based Analysis. Journal of Clinical Oncology, 2022, 40, 1783-1794.	1.6	24
403	A molecular model of type I allergy: Identification and characterization of a nonanaphylactic anti-human IgE antibody fragment that blocks the IgE-FcÏµRI interaction and reacts with receptor-bound IgE. Journal of Allergy and Clinical Immunology, 2001, 108, 409-416.	2.9	23
404	The European Competence Network on Mastocytosis. Wiener Klinische Wochenschrift, 2004, 116, 647-651.	1.9	23
405	The CML-related oncoprotein BCR/ABL induces expression of histidine decarboxylase (HDC) and the synthesis of histamine in leukemic cells. Blood, 2006, 108, 3538-3547.	1.4	23
406	Myelomastocytic leukemia: histopathological features, diagnostic criteria and differential diagnosis. Expert Review of Hematology, 2014, 7, 431-437.	2.2	23
407	Molecular Evolution of Hypoallergenic Hybrid Proteins for Vaccination against Grass Pollen Allergy. Journal of Immunology, 2015, 194, 4008-4018.	0.8	23
408	Incidence of intensive care unit admission, outcome and post intensive care survival in patients with diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2016, 57, 1831-1838.	1.3	23
409	Extracorporeal IgE Immunoadsorption in Allergic Asthma: Safety and Efficacy. EBioMedicine, 2017, 17, 119-133.	6.1	23
410	Gliotoxin Targets Nuclear NOTCH2 in Human Solid Tumor Derived Cell Lines In Vitro and Inhibits Melanoma Growth in Xenograft Mouse Model. Frontiers in Pharmacology, 2017, 8, 319.	3.5	23
411	Risk and management of patients with mastocytosis and MCAS in the SARS-CoV-2 (COVID-19) pandemic: Expert opinions. Journal of Allergy and Clinical Immunology, 2020, 146, 300-306.	2.9	23
412	Genetic Regulation of Tryptase Production and Clinical Impact: Hereditary Alpha Tryptasemia, Mastocytosis and Beyond. International Journal of Molecular Sciences, 2021, 22, 2458.	4.1	23
413	Mediator-Related Symptoms and Anaphylaxis in Children with Mastocytosis. International Journal of Molecular Sciences, 2021, 22, 2684.	4.1	23
414	A STAT5Bâ€“CD9 axis determines self-renewal in hematopoietic and leukemic stem cells. Blood, 2021, 138, 2347-2359.	1.4	23

#	Article	IF	Citations
415	Systemic Mastocytosis. , 2008, 142, 399-419.		23
416	Hitting two oncogenic machineries in cancer cells: cooperative effects of the multi-kinase inhibitor ponatinib and the BET bromodomain blockers JQ1 or dBET1 on human carcinoma cells. Oncotarget, 2018, 9, 26491-26506.	1.8	23
417	The protein tyrosine kinase Tec regulates mast cell function. European Journal of Immunology, 2009, 39, 3228-3238.	2.9	22
418	Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis. Leukemia, 2022, 36, 2108-2120.	7.2	22
419	Purification, Structural and Immunological Characterization of a Timothy Grass (Phleum pratense) Pollen Allergen, Phl p 4, with Cross-Reactive Potential. Biological Chemistry, 2002, 383, 1383-96.	2.5	21
420	Myelodysplastic syndromes, aging, and age: Correlations, common mechanisms, and clinical implications. Leukemia and Lymphoma, 2007, 48, 1900-1909.	1.3	21
421	Multidisciplinary Management of Mastocytosis: Nordic Expert Group Consensus. Acta Dermato-Venereologica, 2016, 96, 602-612.	1.3	21
422	Impact of centralized evaluation of bone marrow histology in systemic mastocytosis. European Journal of Clinical Investigation, 2016, 46, 392-397.	3.4	21
423	Identification of a leukemia-initiating stem cell in human mast cell leukemia. Leukemia, 2019, 33, 2673-2684.	7.2	21
424	Molecular quantification of tissue disease burden is a new biomarker and independent predictor of survival in mastocytosis. Haematologica, 2020, 105, 366-374.	3.5	21
425	Clinical Impact of Inherited and Acquired Genetic Variants in Mastocytosis. International Journal of Molecular Sciences, 2021, 22, 411.	4.1	21
426	Nintedanib targets KIT D816V neoplastic cells derived from induced pluripotent stem cells of systemic mastocytosis. Blood, 2021, 137, 2070-2084.	1.4	21
427	High-Level Expression inEscherichia coliand Purification of Recombinant Plant Profilins: Comparison of IgE-Binding Capacity and Allergenic Activity. Biochemical and Biophysical Research Communications, 1996, 226, 42-50.	2.1	20
428	Molecular characterization of recombinant T1, a non-allergenic periwinkle (Catharanthus roseus) protein, with sequence similarity to the Bet v 1 plant allergen family. Biochemical Journal, 2003, 373, 261-269.	3.7	20
429	Validation of cytogenetic risk groups according to International Prognostic Scoring Systems by peripheral blood CD34+FISH: results from a German diagnostic study in comparison with an international control group. Haematologica, 2015, 100, 205-213.	3.5	20
430	Chronic mast cell leukemia (MCL) with KIT S476I: a rare entity defined by leukemic expansion of mature mast cells and absence of organ damage. Annals of Hematology, 2015, 94, 223-231.	1.8	20
431	Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes: Analysis from the International Working Group for Prognosis of MDS. Leukemia Research, 2018, 73, 51-57.	0.8	20
432	Activation of Siglec-7 results in inhibition of in vitro and in vivo growth of human mast cell leukemia cells. Pharmacological Research, 2020, 158, 104682.	7.1	20

#	Article	IF	Citations
433	Standards of Genetic Testing in the Diagnosis and Prognostication of Systemic Mastocytosis in 2022: Recommendations of the EU-US Cooperative Group. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 1953-1963.	3.8	20
434	Division of the Major Birch Pollen Allergen, Bet v 1, into Two Non-Anaphylactic Fragments. International Archives of Allergy and Immunology, 1997, 113, 246-248.	2.1	19
435	IgA cross-reactivity between a nuclear autoantigen and wheat proteins suggests molecular mimicry as a possible pathomechanism in celiac disease. European Journal of Immunology, 2001, 31, 918-928.	2.9	19
436	Targeting of heat-shock protein 32/heme oxygenase-1 in canine mastocytoma cells is associated with reduced growth and induction of apoptosis. Experimental Hematology, 2008, 36, 1461-1470.	0.4	19
437	Evaluation of in vivo antineoplastic effects of rapamycin in patients with chemotherapy-refractory AML. European Journal of Internal Medicine, 2009, 20, 775-778.	2.2	19
438	The classification of systemic mastocytosis should include mast cell leukemia (MCL) and systemic mastocytosis with a clonal hematologic nonâ€“mast cell lineage disease (SM-AHNMD). Blood, 2010, 116, 850-851.	1.4	19
439	The impact of molecular targets in cancer drug development: major hurdles and future strategies. Expert Review of Clinical Pharmacology, 2013, 6, 23-34.	3.1	19
440	Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study. International Journal of Molecular Sciences, 2017, 18, 837.	4.1	19
441	The <scp>JAK2</scp>/<scp>STAT5</scp> signaling pathway as a potential therapeutic target in canine mastocytoma. Veterinary and Comparative Oncology, 2018, 16, 55-68.	1.8	19
442	Emerging therapeutic targets in myeloproliferative neoplasms and peripheral T-cell leukemia and lymphomas. Expert Opinion on Therapeutic Targets, 2018, 22, 45-57.	3.4	19
443	CEBPA-mutated leukemia is sensitive to genetic and pharmacological targeting of the MLL1 complex. Leukemia, 2019, 33, 1608-1619.	7.2	19
444	KIT Inhibitor Midostaurin in Patients with Advanced Systemic Mastocytosis: Results of a Planned Interim Analysis of the Global CPKC412D2201 Trial. Blood, 2012, 120, 799-799.	1.4	19
445	Maintenance therapy with histamine plus IL-2 induces a striking expansion of two CD56bright NK cell subpopulations in patients with acute myeloid leukemia and supports their activation. Oncotarget, 2016, 7, 46466-46481.	1.8	19
446	Identification of heat shock protein 32 (Hsp32) as a novel target in acute lymphoblastic leukemia. Oncotarget, 2014, 5, 1198-1211.	1.8	19
447	Clinical impact and proposed application of molecular markers, genetic variants, and cytogenetic analysis in mast cell neoplasms: Status 2022. Journal of Allergy and Clinical Immunology, 2022, 149, 1855-1865.	2.9	19
448	High dose intermittent ARA-C (HiDAC) for consolidation of patients with de novo AML: a single center experience. Leukemia Research, 2005, 29, 609-615.	0.8	18
449	Autocrine fibroblast growth factor 18 signaling mediates Wnt-dependent stimulation of CD44-positive human colorectal adenoma cells. Molecular Carcinogenesis, 2015, 54, 789-799.	2.7	18
450	Preclinical human models and emerging therapeutics for advanced systemic mastocytosis. Haematologica, 2018, 103, 1760-1771.	3.5	18

#	Article	IF	Citations
451	CD44 is a RAS/STAT5-regulated invasion receptor that triggers disease expansion in advanced mastocytosis. Blood, 2018, 132, 1936-1950.	1.4	18
452	Comparative oncology: The paradigmatic example of canine and human mast cell neoplasms. Veterinary and Comparative Oncology, 2019, 17, 1-10.	1.8	18
453	The Austrian biodatabase for chronic myelomonocytic leukemia (ABCMML). Wiener Klinische Wochenschrift, 2019, 131, 410-418.	1.9	18
454	TGFÎ²R-SMAD3 Signaling Induces Resistance to PARP Inhibitors in the Bone Marrow Microenvironment. Cell Reports, 2020, 33, 108221.	6.4	18
455	Imatinib-resistant chronic myeloid leukemia (CML): Current concepts on pathogenesis and new emerging pharmacologic approaches. Biologics: Targets and Therapy, 2007, 1, 433-48.	3.2	18
456	Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European <scp>LeukemiaNet</scp> International <scp>MDSâ€Flow</scp> Cytometry Working Group. Cytometry Part B - Clinical Cytometry, 2023, 104, 77-86.	1.5	18
457	Drug-induced mast cell eradication: AÂnovel approach to treat mast cell activation disorders?. Journal of Allergy and Clinical Immunology, 2022, 149, 1866-1874.	2.9	18
458	FDG Positron Emission Tomography in Patients with Systemic Mastocytosis. American Journal of Roentgenology, 2002, 179, 1235-1237.	2.2	17
459	Quantitation of Minimal Residual Disease in Acute Myeloid Leukemia by Tryptase Monitoring Identifies a Group of Patients with a High Risk of Relapse. Clinical Cancer Research, 2005, 11, 6536-6543.	7.0	17
460	Indolent systemic mastocytosis associated with atypical small lymphocytic lymphoma: a rare form of concomitant lymphoproliferative disease. Human Pathology, 2008, 39, 917-924.	2.0	17
461	Growth-inhibitory effects of four tyrosine kinase inhibitors on neoplastic feline mast cells exhibiting a Kit exon 8 ITD mutation. Veterinary Immunology and Immunopathology, 2009, 132, 243-250.	1.2	17
462	Polo-like kinase-1 as a novel target in neoplastic mast cells: demonstration of growth-inhibitory effects of small interfering RNA and the Polo-like kinase-1 targeting drug BI 2536. Haematologica, 2011, 96, 672-680.	3.5	17
463	Controversies and Open Questions in the Definitions and Classification of the Hypereosinophilic Syndromes and Eosinophilic Leukemias. Seminars in Hematology, 2012, 49, 171-181.	3.4	17
464	Cold antibody autoimmune hemolytic anemia and lymphoproliferative disorders: a retrospective study of 20 patients including clinical, hematological, and molecular findings. Wiener Klinische Wochenschrift, 2014, 126, 376-382.	1.9	17
465	Coreâ€binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (Iâ€•CBF) Tj ETQq1 1 0.784314 rgBT	2.8	17
466	Mastocytosis: a paradigmatic example of a rare disease with complex biology and pathology. American Journal of Cancer Research, 2013, 3, 159-72.	1.4	17
467	Tyrosine kinase inhibitors for the treatment of indolent systemic mastocytosis: Are we there yet?. Journal of Allergy and Clinical Immunology, 2022, 149, 1912-1918.	2.9	17
468	Does Cord Blood Contain Enough Progenitor Cells for Transplantation?. Stem Cells and Development, 1994, 3, 291-298.	1.0	16

#	Article	IF	Citations
469	Mast cells, thrombosis, and fibrinolysis. Thrombosis Research, 2002, 105, 359-365.	1.7	16
470	Induction of Apoptosis in the Human Mast Cell Leukemia Cell Line HMC-1 by Various Antineoplastic Drugs. Leukemia and Lymphoma, 2003, 44, 509-515.	1.3	16
471	Expression of Cell Surface Antigens on Mast Cells: Mast Cell Phenotyping. , 2006, 315, 077-090.		16
472	Trimolecular Complex Formation of IgE, FcÎµRI, and a Recombinant Nonanaphylactic Single-Chain Antibody Fragment with High Affinity for IgE. Journal of Immunology, 2009, 182, 4817-4829.	0.8	16
473	E- and P-Selectins Are Essential for Repopulation of Chronic Myelogenous and Chronic Eosinophilic Leukemias in a Scid Mouse Xenograft Model. PLoS ONE, 2013, 8, e70139.	2.5	16
474	Evaluation of cooperative antileukemic effects of nilotinib and vildagliptin in Ph+ chronic myeloid leukemia. Experimental Hematology, 2018, 57, 50-59.e6.	0.4	16
475	The Mastocytosis Society Survey on Mast Cell Disorders: Part 2â€"Patient Clinical Experiences and Beyond. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 1157-1165.e6.	3.8	16
476	COVID-19 infection in patients with mast cell disorders including mastocytosis does not impact mast cell activation symptoms. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 2083-2086.	3.8	16
477	Identification of Basogranulin (BB1) as a Novel Immunohistochemical Marker of Basophils in Normal Bone Marrow and Patients With Myeloproliferative Disorders. American Journal of Clinical Pathology, 2006, 125, 273-281.	0.7	16
478	Guidelines and diagnostic algorithm for patients with suspected systemic mastocytosis: a proposal of the Austrian competence network (AUCNM). American Journal of Blood Research, 2013, 3, 174-80.	0.6	16
479	Flow cytometric analysis of myelodysplasia: Preâ€analytical and technical issuesâ€"Recommendations from the European <scp>LeukemiaNet</scp>. Cytometry Part B - Clinical Cytometry, 2023, 104, 15-26.	1.5	16
480	Proposed Diagnostic Criteria and Classification of Canine Mast Cell Neoplasms: A Consensus Proposal. Frontiers in Veterinary Science, 2021, 8, 755258.	2.2	16
481	Splenic Mastocytosis: Report of Two Cases and Detection of the Transforming SomaticC-KITMutation D816V. Leukemia and Lymphoma, 2004, 45, 723-729.	1.3	15
482	Standard treatment of Ph+ CML in 2010: how, when and where not to use what BCR/ABL1 kinase inhibitor?. European Journal of Clinical Investigation, 2010, 40, 918-931.	3.4	15
483	A Target-Disease Network Model of Second-Generation BCR-ABL Inhibitor Action in Ph+ ALL. PLoS ONE, 2013, 8, e77155.	2.5	15
484	Phenotyping of Human Melanoma Cells Reveals a Unique Composition of Receptor Targets and a Subpopulation Co-Expressing ErbB4, EPO-R and NGF-R. PLoS ONE, 2014, 9, e84417.	2.5	15
485	Redistribution, homing and organ-invasion of neoplastic stem cells in myeloid neoplasms. Seminars in Cancer Biology, 2020, 60, 191-201.	9.6	15
486	Searching for Pareto Fronts for Forest Stand Wind Stability by Incorporating Timber and Biodiversity Values. Forests, 2020, 11, 583.	2.1	15

#	Article	IF	Citations
487	Midostaurin (PKC412) Demonstrates a High Rate of Durable Responses in Patients with Advanced Systemic Mastocytosis: Results from the Fully Accrued Global Phase 2 CPKC412D2201 Trial. Blood, 2014, 124, 636-636.	1.4	15
488	Immunohistochemical Detection of VEGF in the Bone Marrow of Patients With Acute Myeloid Leukemia: Correlation Between VEGF Expression and the FAB Category. American Journal of Clinical Pathology, 2003, 119, 663-671.	0.7	15
489	The impact of <scp>COVID</scp>â€19 on cancer care of outpatients with low socioeconomic status. International Journal of Cancer, 2022, 151, 77-82.	5.1	15
490	Recombinant human megakaryocyte growth and development factor increases levels of circulating haemopoietic progenitor cells post chemotherapy in patients with acute myeloid leukaemia. British Journal of Haematology, 1998, 102, 535-543.	2.5	14
491	Autoantibody Reactivity in a Case of Schnitzlerâ€™s Syndrome: Evidence for a Th1-Like Response and Detection of IgG2 Anti-FcÎµRIÎ± Antibodies. International Archives of Allergy and Immunology, 2000, 122, 279-286.	2.1	14
492	Targeted genes in haematology. European Journal of Clinical Investigation, 2004, 34, 1-1.	3.4	14
493	Immunohistochemical detection of histidine decarboxylase in neoplastic mast cells in patients with systemic mastocytosisâ¯†. Human Pathology, 2006, 37, 439-447.	2.0	14
494	Improved Outcome in Patients with Chronic Myelogenous Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation Over the Past 25 Years: A Single-Center Experience. Biology of Blood and Marrow Transplantation, 2011, 17, 133-140.	2.0	14
495	Monoclonal Bâ€cell lymphocytosis (MBL) with normal lymphocyte counts is associated with decreased numbers of normal circulating Bâ€cell subsets. American Journal of Hematology, 2012, 87, 721-724.	4.1	14
496	CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1T315I+ clones in TKI-resistant CML. EBioMedicine, 2019, 50, 111-121.	6.1	14
497	An increased bone mineral density is an adverse prognostic factor in patients with systemic mastocytosis. Journal of Cancer Research and Clinical Oncology, 2020, 146, 945-951.	2.5	14
498	KIT D816V and the cytokine storm in mastocytosis: production and role of interleukin-6. Haematologica, 2020, 105, 5-6.	3.5	14
499	Clinical Impact of Skin Lesions in Mastocytosis: A Multicenter Study of the European Competence Network on Mastocytosis. Journal of Investigative Dermatology, 2021, 141, 1719-1727.	0.7	14
500	Identification of CAR As a Novel Mediator of Erythroid Differentiation and Migration That Is Specifically Downregulated in Erythropoietic Progenitor Cells in Patients with MDS. Blood, 2014, 124, 1570-1570.	1.4	14
501	<scp>BRD4</scp> degradation blocks expression of <scp>MYC</scp> and multiple forms of stem cell resistance in Ph⁺ chronic myeloid leukemia. American Journal of Hematology, 2022, 97, 1215-1225.	4.1	14
502	Immunophenotypic Characterization of Human Basophils and Mast Cells. Chemical Immunology and Allergy, 1995, 61, 34-48.	1.7	13
503	Sustained remission including marked regression of a paravertebral plasmacytoma in a patient with heavily pretreated, relapsed multiple myeloma after treatment with bortezomib. Leukemia Research, 2005, 29, 1473-1477.	0.8	13
504	Low erythropoietin production as non-oncogenic co-factor contributing to disease-manifestation in low-risk MDS: A hypothesis supported by unique case reports. Leukemia Research, 2008, 32, 1333-1337.	0.8	13

#	Article	IF	Citations
505	Lenalidomide therapy in systemic mastocytosis. Leukemia Research, 2009, 33, e19-e22.	0.8	13
506	Comparative analysis of <scp>IL</scp>6 and <scp>IL</scp>6 receptor gene polymorphisms in mastocytosis. British Journal of Haematology, 2013, 160, 216-219.	2.5	13
507	Anti-Fas/CD95 and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) differentially regulate apoptosis in normal and neoplastic human basophils. Leukemia and Lymphoma, 2013, 54, 835-842.	1.3	13
508	In vitro and in vivo effects of <scp>JAK</scp>2 inhibition in chronic myelomonocytic leukemia. European Journal of Haematology, 2016, 97, 562-567.	2.2	13
509	Functional characterization, localization, and inhibitor sensitivity of the <scp>TPRâ€FGFR1</scp> fusion in 8p11 myeloproliferative syndrome. Genes Chromosomes and Cancer, 2016, 55, 60-68.	2.8	13
510	Therapeutic Vulnerabilities in FLT3-Mutant AML Unmasked by Palbociclib. International Journal of Molecular Sciences, 2018, 19, 3987.	4.1	13
511	Effects of ibrutinib on proliferation and histamine release in canine neoplastic mast cells. Veterinary and Comparative Oncology, 2019, 17, 553-561.	1.8	13
512	Scoring the Risk of Having Systemic Mastocytosis in Adult Patients with Mastocytosis in the Skin. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 1705-1712.e4.	3.8	13
513	TKI rotation-induced persistent deep molecular response in multi-resistant blast crisis of Ph+ CML. Oncotarget, 2017, 8, 23061-23072.	1.8	13
514	The pan-BCL-2-blocker obatoclax (GX15-070) and the PI3-kinase/mTOR-inhibitor BEZ235 produce cooperative growth-inhibitory effects in ALL cells. Oncotarget, 2017, 8, 67709-67722.	1.8	13
515	Effects of dental amalgam and heavy metal cations on cytokine production by peripheral blood mononuclear cellsin vitro. , 1998, 42, 76-84.		12
516	Amplification of ribosomal RNA genes in acute myeloid leukemia. Genes Chromosomes and Cancer, 2001, 32, 11-17.	2.8	12
517	Response to the letter of Dr. Karin Hartmann and Dr. Beate M. Henz. Leukemia Research, 2002, 26, 485-486.	0.8	12
518	Ph-Chromosome-positive chronic myeloid leukemia with associated bone marrow mastocytosis. Leukemia Research, 2005, 29, 1227-1232.	0.8	12
519	Treatment of refractory or relapsed acquired aplastic anemia: review of established and experimental approaches. Leukemia and Lymphoma, 2011, 52, 1435-1445.	1.3	12
520	Eosinophil, basophil, and mast cell infiltrates in the bone marrow: crossing the boundaries of diagnosis. Journal of Hematopathology, 2011, 4, 101-111.	0.4	12
521	Prognosis of acute myeloid leukemia transformed from myelodysplastic syndromes: A multicenter retrospective study. Leukemia Research, 2013, 37, 862-867.	0.8	12
522	Proposed score for survival of patients with myelodysplastic syndromes. European Journal of Clinical Investigation, 2013, 43, 1120-1128.	3.4	12

#	Article	IF	Citations
523	FLAG-induced remission in a patient with acute mast cell leukemia (MCL) exhibiting t(7;10)(q22;q26) and KIT D816H. Leukemia Research Reports, 2014, 3, 8-13.	0.4	12
524	Probability of remaining in unsustained complete remission after steroid therapy withdrawal in patients with primary warm-antibody reactive autoimmune hemolytic anemia. Wiener Klinische Wochenschrift, 2016, 128, 234-237.	1.9	12
525	Non-NAD-like PARP1 inhibitor enhanced synthetic lethal effect of NAD-like PARP inhibitors against BRCA1-deficient leukemia. Leukemia and Lymphoma, 2019, 60, 1098-1101.	1.3	12
526	Clonal Hematopoiesis of Indeterminate Potential: A Multidisciplinary Challenge in Personalized Hematology. Journal of Personalized Medicine, 2020, 10, 94.	2.5	12
527	STAT5 is Expressed in CD34+/CD38â^' Stem Cells and Serves as a Potential Molecular Target in Ph-Negative Myeloproliferative Neoplasms. Cancers, 2020, 12, 1021.	3.7	12
528	Core-binding factor leukemia hijacks the T-cellâ€“prone PU.1 antisense promoter. Blood, 2021, 138, 1345-1358.	1.4	12
529	Transposon-mediated generation of BCR-ABL1-expressing transgenic cell lines for unbiased sensitivity testing of tyrosine kinase inhibitors. Oncotarget, 2016, 7, 78083-78094.	1.8	12
530	Why clinicians should be interested in Interleukin-3. Blut, 1990, 61, 338-345.	1.2	11
531	Characterization of LDL and VLDL Binding Sites on Human Basophils and Mast Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 1995, 15, 17-26.	2.4	11
532	Evaluation of biologic activity of tryptase secreted from blast cells in acute myeloid leukemia. Leukemia and Lymphoma, 2006, 47, 897-906.	1.3	11
533	New developments in the field of mastocytosis and mast cell activation syndromes: a summary of the Annual Meeting of the European Competence Network on Mastocytosis (ECNM) 2019. Leukemia and Lymphoma, 2020, 61, 1075-1083.	1.3	11
534	Oligo-monocytic CMML and other pre-CMML states: Clinical impact, prognostication and management. Best Practice and Research in Clinical Haematology, 2020, 33, 101137.	1.7	11
535	Cell-based and antibody-mediated immunotherapies directed against leukemic stem cells in acute myeloid leukemia: Perspectives and open issues. Stem Cells Translational Medicine, 2020, 9, 1331-1343.	3.3	11
536	Correlation of RAS-Pathway Mutations and Spontaneous Myeloid Colony Growth with Progression and Transformation in Chronic Myelomonocytic Leukemiaâ€"A Retrospective Analysis in 337 Patients. International Journal of Molecular Sciences, 2020, 21, 3025.	4.1	11
537	Precision Medicine in Hematology 2021: Definitions, Tools, Perspectives, and Open Questions. HemaSphere, 2021, 5, e536.	2.7	11
538	Idiopathic bone marrow dysplasia of unknown significance (IDUS): definition, pathogenesis, follow up, and prognosis. American Journal of Cancer Research, 2011, 1, 531-41.	1.4	11
539	Long-lasting complete response to imatinib in a patient with systemic mastocytosis exhibiting wild type KIT. American Journal of Blood Research, 2014, 4, 93-100.	0.6	11
540	Improvement of cardiac function, mitral regurgitation and pulmonary hypertension in a patient with chronic eosinophilic leukemia (CEL) after low dose imatinib therapy. Leukemia Research, 2008, 32, 1779-1783.	0.8	10

#	Article	IF	Citations
541	Interleukin-33: a regulator of basophils. Blood, 2009, 113, 1396-1397.	1.4	10
542	KIT polymorphisms and mutations determine responses of neoplastic mastÂcells to bafetinib (INNO-406). Experimental Hematology, 2010, 38, 782-791.	0.4	10
543	Karyotype plus NPM1 mutation status defines a group of elderly patients with AML (â‰¥60 years) who benefit from intensive postâ€induction consolidation therapy. American Journal of Hematology, 2016, 91, 1239-1245.	4.1	10
544	Variability of PD-L1 expression in mastocytosis. Blood Advances, 2018, 2, 189-199.	5.2	10
545	Results from a Genome-Wide Association Study (GWAS) in Mastocytosis Reveal New Gene Polymorphisms Associated with WHO Subgroups. International Journal of Molecular Sciences, 2020, 21, 5506.	4.1	10
546	Impact of age on the cumulative risk of transformation in patients with chronic myelomonocytic leukaemia. European Journal of Haematology, 2021, 107, 265-274.	2.2	10
547	Clinical and histopathological features of myeloid neoplasms with concurrent Janus kinase 2 (JAK2) V617F and KIT protoâ€oncogene, receptor tyrosine kinase (KIT) D816V mutations. British Journal of Haematology, 2021, 194, 344-354.	2.5	10
548	Expression of fibrinolytic antigens in redistributed cardiac mast cells in auricular thrombosis. Human Pathology, 1997, 28, 1283-1290.	2.0	9
549	Effect of statins on lipoprotein receptor expression in cell lines from human mast cells and basophils. European Journal of Clinical Pharmacology, 2003, 59, 507-516.	1.9	9
550	Evaluation of normal and neoplastic human mast cells for expression of CD172a (SIRPÎ±), CD47, and SHP-1. Journal of Leukocyte Biology, 2005, 77, 984-992.	3.3	9
551	Diagnostic algorithms, monitoring, prognostication, and therapy in chronic myeloid leukemia (CML): a proposal of the Austrian CML platform. Wiener Klinische Wochenschrift, 2008, 120, 697-709.	1.9	9
552	The Transcription Factor MAZR Preferentially Acts as a Transcriptional Repressor in Mast Cells and Plays a Minor Role in the Regulation of Effector Functions in Response to FcÎµRI Stimulation. PLoS ONE, 2013, 8, e77677.	2.5	9
553	Intensive consolidation with Gâ€CSF support: Tolerability, safety, reduced hospitalization, and efficacy in acute myeloid leukemia patients â‰¥60 years. American Journal of Hematology, 2017, 92, E567-E574.	4.1	9
554	The Italian Mastocytosis Registry: 6-year experience from a hospital-based registry. Future Oncology, 2018, 14, 2713-2723.	2.4	9
555	miRNome profiling of LSC-enriched CD34+CD38â^'CD26+ fraction in Ph+ CML-CP samples from Argentinean patients: a potential new pharmacogenomic tool. Frontiers in Pharmacology, 2020, 11, 612573.	3.5	9
556	Ponatinib Exerts Multiple Effects on Vascular Endothelial Cells: Possible Mechanisms and Explanations for the Adverse Vascular Events Seen in CML Patients Treated with Ponatinib. Blood, 2016, 128, 1883-1883.	1.4	9
557	Update on genetic and molecular markers associated with myelodysplastic syndromes. Leukemia and Lymphoma, 2009, 50, 341-348.	1.3	8
558	Stable non-transforming minimal residual disease in Philadelphia chromosome positive acute lymphoblastic leukemia after autologous transplantation: origin from neoplastic yet â€˜pre-leukemicâ€™ stem cells?. Leukemia and Lymphoma, 2011, 52, 842-848.	1.3	8

#	Article	IF	Citations
559	Nilotinib as frontline and second-line therapy in chronic myeloid leukemia: Open questions. Critical Reviews in Oncology/Hematology, 2012, 82, 370-377.	4.4	8
560	Frequency of del(12p) is commonly underestimated in myelodysplastic syndromes: Results from a ‹scp›G‹/scp›erman diagnostic study in comparison with an international control group. Genes Chromosomes and Cancer, 2015, 54, 809-817.	2.8	8
561	cFinder: definition and quantification of multiple haplotypes in a mixed sample. BMC Research Notes, 2015, 8, 422.	1.4	8
562	Antibody conjugates bispecific for intercellular adhesion molecule 1 and allergen prevent migration of allergens through respiratory epithelial cell layers. Journal of Allergy and Clinical Immunology, 2015, 136, 490-493.e11.	2.9	8
563	Emerging translational science discoveries, clonal approaches, and treatment trends in chronic myeloproliferative neoplasms. Hematological Oncology, 2019, 37, 240-252.	1.7	8
564	Microarray-Based Detection of Allergen-Reactive IgE in Patients with Mastocytosis. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 2761-2768.e16.	3.8	8
565	A Challenge for Allergologist: Application of Allergy Diagnostic Methods in Mast Cell Disorders. International Journal of Molecular Sciences, 2021, 22, 1454.	4.1	8
566	Phenotypic characterization of leukemia-initiating stem cells in chronic myelomonocytic leukemia. Leukemia, 2021, 35, 3176-3187.	7.2	8
567	Recombinant Allergens. Advances in Experimental Medicine and Biology, 1996, , 185-196.	1.6	8
568	Immunohistochemical Detection of VEGF in the Bone Marrow of Patients With Chronic Myeloid Leukemia and Correlation With the Phase of Disease. American Journal of Clinical Pathology, 2004, 121, 473-481.	0.7	8
569	Phase I/II Study of BI 2536, An Intravenous Polo-Like Kinase-1 (Plk-1) Inhibitor, in Elderly Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML): First Results of a Multi-Center Trial. Blood, 2008, 112, 2973-2973.	1.4	8
570	‹scp›PDâ€Ł1‹/scp› overexpression correlates with ‹scp›‹i›JAK2‹/i›â€V617F‹/scp› mutational burden and is associated with 9p uniparental disomy in myeloproliferative neoplasms. American Journal of Hematology, 2022, 97, 390-400.	4.1	8
571	Immunophenotypic Analysis of HL-60 Cells during Basophilic Differentiation. International Archives of Allergy and Immunology, 1996, 110, 252-260.	2.1	7
572	Detection of Trisomy 8 in Donor-Derived Phâ”Cells in a Patient with Ph+Chronic Myeloid Leukemia Successfully Treated with Imatinib (STI571) in Relapse after Allogeneic Transplantation. Leukemia and Lymphoma, 2004, 45, 1453-1458.	1.3	7
573	Growing Evidence for an Underestimation of Poor-Risk Cytogenetics in the International Prognostic Scoring System in Myelodysplastic Syndromes. Clinical Leukemia, 2007, 1, 353-356.	0.2	7
574	A patient with de novo AML M1 and t(16;21) with karyotype evolution. Leukemia Research, 2007, 31, 1319-1321.	0.8	7
575	Clinical perspectives of concepts on neoplastic stem cells and stem cell-resistance in chronic myeloid leukemia. Leukemia and Lymphoma, 2008, 49, 604-609.	1.3	7
576	Does highâ€dose cytarabine cause cumulative toxicity in patients undergoing consolidation therapy for acute myeloid leukemia?. American Journal of Hematology, 2013, 88, 533-534.	4.1	7

#	Article	IF	Citations
577	Evaluation of treatment responses and colony-forming progenitor cells in 50 patients with aplastic anemia after immunosuppressive therapy or hematopoietic stem cell transplantation: a single-center experience. Wiener Klinische Wochenschrift, 2014, 126, 119-125.	1.9	7
578	Dasatinib-induced immunosuppression and recurrent respiratory tract infections. Leukemia and Lymphoma, 2015, 56, 2484-2485.	1.3	7
579	Allogeneic hematopoietic cell transplantation in systemic mastocytosis: is there a high risk for venoâ€occlusive disease?. European Journal of Haematology, 2016, 96, 655-657.	2.2	7
580	Targeting Nuclear NOTCH2 by Gliotoxin Recovers a Tumor-Suppressor NOTCH3 Activity in CLL. Cells, 2020, 9, 1484.	4.1	7
581	Practical management of adverse events in patients with advanced systemic mastocytosis receiving midostaurin. Expert Opinion on Biological Therapy, 2021, 21, 487-498.	3.1	7
582	Forest modelling and visualisation â€“ state of the art and perspectives. Central European Forestry Journal, 2019, 65, 147-165.	0.8	7
583	Prominin-1 (CD133, AC133) and dipeptidyl-peptidase IV (CD26) are indicators of infinitive growth in colon cancer cells. American Journal of Cancer Research, 2015, 5, 560-74.	1.4	7
584	Metabolic drug survey highlights cancer cell dependencies and vulnerabilities. Nature Communications, 2021, 12, 7190.	12.8	7
585	The cancer survival indexâ€”A prognostic score integrating psychosocial and biological factors in patients diagnosed with cancer or haematologic malignancies. Cancer Medicine, 2022, 11, 3387-3396.	2.8	7
586	Signal Transductionâ€”Associated and Cell Activationâ€”Linked Antigens Expressed in Human Mast Cells. International Journal of Hematology, 2002, 75, 357-362.	1.6	6
587	Normal bone marrow function over 6 years in a patient with dysplastic hematopoiesis and a complex karyotype. Leukemia Research, 2004, 28, 651-655.	0.8	6
588	Expression of a Major Plant Allergen as Membrane-Anchored and Secreted Protein in Human Cells with Preserved T Cell and B Cell Epitopes. International Archives of Allergy and Immunology, 2011, 156, 259-266.	2.1	6
589	In vitro effects of histamine receptor 1 antagonists on proliferation and histamine release in canine neoplastic mast cells. Veterinary Medicine and Science, 2021, 7, 57-68.	1.6	6
590	Coreâ€binding factor acute myeloid leukemia with inv(16): Older age and high white blood cell count are risk factors for treatment failure. International Journal of Laboratory Hematology, 2021, 43, e19-e25.	1.3	6
591	Epigenetic Changes in Neoplastic Mast Cells and Potential Impact in Mastocytosis. International Journal of Molecular Sciences, 2021, 22, 2964.	4.1	6
592	Culturing cells with mast cell phenotype and function: Comparison of peripheral blood and bone marrow as a source.. Journal of Immunological Methods, 2021, 495, 113061.	1.4	6
593	Delineation of a KIT-Independent Oncogenic Pathway in Neoplastic Mast Cells That Involves Lyn and Btk, and Can Be Disrupted by the KIT/Lyn/Btk-Targeting Drug Dasatinib. Blood, 2007, 110, 1541-1541.	1.4	6
594	Nilotinib Exerts Direct Effects on Vascular Endothelial Cells and May Act As a Co-Trigger of Atherosclerosis in Patients with Ph+ CML. Blood, 2011, 118, 2753-2753.	1.4	6

#	Article	IF	Citations
595	Durable Responses and Improved Quality Of Life With Midostaurin (PKC412) In Advanced Systemic Mastocytosis (SM): Updated Stage 1 Results Of The Global D2201 Trial. Blood, 2013, 122, 106-106.	1.4	6
596	Identification of a Neoplastic Stem Cell in Human Mast Cell Leukemia. Blood, 2014, 124, 817-817.	1.4	6
597	Interleukin-9 (IL-9) and NPM-ALK each generate mast cell hyperplasia as single â€˜hitâ€™ and cooperate in producing a mastocytosis-like disease in mice. Oncotarget, 2010, 1, 104-119.	1.8	6
598	Evaluation of in vitro effects of various targeted drugs on plasma cells and putative neoplastic stem cells in patients with multiple myeloma. Oncotarget, 2016, 7, 65627-65642.	1.8	6
599	The c-kit Ligand Stem Cell Factor and Anti-IgE Promote Expression of Monocyte Chemoattractant Protein-1 in Human Lung Mast Cells. Blood, 1997, 90, 4438-4449.	1.4	6
600	Deciphering the Mechanisms of Osteoblast-Induced Resistance of Leukemic Stem Cell (LSC) in Ph+ CML: Role of PI3-Kinase, BRD4 and MYC and Development of Strategies to Overcome Osteoblast-Induced Resistance. Blood, 2021, 138, 1481-1481.	1.4	6
601	Treatment of de novo acute myelogenous leukemia with recombinant granulocyte macrophage-colony-stimulating factor in combination with standard induction chemotherapy: Effect of granulocyte macrophage-colony-stimulating factor on white blood cell counts. Medical and Pediatric Oncology, 1992, 20, 18-22.	1.0	5
602	Treatment concepts for elderly patients with acute myeloid leukemia. Wiener Klinische Wochenschrift, 2003, 115, 505-514.	1.9	5
603	Immunological Characterization and Antibacterial Function of Persisting Granulocytes in Leukemic Patients Receiving Pulse Cytosine Arabinoside-Consolidation Chemotherapy on Days 1, 3, and 5. Journal of Immunology, 2006, 176, 1759-1768.	0.8	5
604	Biology and clinical features of myeloid neoplasms with inv(3) (q21q26) or t(3;3) (q21q26). Leukemia and Lymphoma, 2007, 48, 2096-2097.	1.3	5
605	Characterization of mutants of a highly cross-reactive calcium-binding protein from Brassica pollen for allergen-specific immunotherapy. Immunobiology, 2013, 218, 1155-1165.	1.9	5
606	Mast cell leukemia: a review. International Journal of Hematologic Oncology, 2014, 3, 395-405.	1.6	5
607	A phase I study of lenalidomide in patients with chronic myelomonocytic leukemia (CMML) â€“ AGMT_CMML-1. Leukemia and Lymphoma, 2018, 59, 1121-1126.	1.3	5
608	Molecular Basis and Clinical Application of Growth-Factor-Independent In Vitro Myeloid Colony Formation in Chronic Myelomonocytic Leukemia. International Journal of Molecular Sciences, 2020, 21, 6057.	4.1	5
609	BRD4 Degradation Is a Potent Approach to Block MYC Expression and to Overcome Multiple Forms of Stem Cell Resistance in Ph+ CML. Blood, 2018, 132, 1722-1722.	1.4	5
610	Further Evaluation of Pro-Atherogenic and Anti-Angiogenic Effects of Nilotinib in Mice and in Patients with Ph-Chromosome+ CML. Blood, 2014, 124, 1800-1800.	1.4	5
611	A Novel Fusion Gene NDEL1-Pdgfrb in a Patient with JMML with a New Variant of TKI-Resistant Mutation in the Kinase Domain of PDGFRI². Blood, 2014, 124, 613-613.	1.4	5
612	An Analysis of Prognostic Markers and the Performance of Scoring Systems in 1837 Patients with Therapy-Related Myelodysplastic Syndrome - a Study of the International Working Group (IWG-PM) for Myelodysplastic Syndromes (MDS). Blood, 2015, 126, 609-609.	1.4	5

#	Article	IF	Citations
613	Serum-tryptase at diagnosis: a novel biomarker improving prognostication in Ph(+) CML. American Journal of Cancer Research, 2015, 5, 354-62.	1.4	5
614	A series of case studies illustrating the role of flow cytometry in the diagnostic workâ€up of myelodysplastic syndromes. Cytometry Part B - Clinical Cytometry, 2022, , .	1.5	5
615	Overexpression of FcÎµRI on Bone Marrow Mast Cells, but Not MRGPRX2, in Clonal Mast Cell Disorders With Wasp Venom Anaphylaxis. Frontiers in Immunology, 2022, 13, 835618.	4.8	5
616	Pathogenesis, classification, and treatment of myelodysplastic syndromes (MDS). Wiener Klinische Wochenschrift, 2003, 115, 515-536.	1.9	4
617	Mast cells, masters, and mastocytosis: Development of research since the times of Paul Ehrlich. Wiener Klinische Wochenschrift, 2004, 116, 645-646.	1.9	4
618	An unusual case of myelodysplastic syndrome with prolonged clonal stability, indolent clinical course over a decade, and spontaneous regression of AML in the terminal phase. European Journal of Haematology, 2005, 75, 73-77.	2.2	4
619	First annual report of the Austrian CML registry. Wiener Klinische Wochenschrift, 2010, 122, 558-566.	1.9	4
620	Diagnosis and Treatment of Anaphylaxis in Patients with Mastocytosis. Current Treatment Options in Allergy, 2014, 1, 247-261.	2.2	4
621	Evaluation of efficacy of alemtuzumab in 5 patients with aplastic anemia and/or myelodysplastic neoplasm. Wiener Klinische Wochenschrift, 2017, 129, 404-410.	1.9	4
622	Switching From Highâ€Dose Eculizumab to Ravulizumab in Paroxysmal Nocturnal Hemoglobinuria: A Case Report. HemaSphere, 2020, 4, e455.	2.7	4
623	Physiology and pathology of eosinophils: Recent developments. Scandinavian Journal of Immunology, 2021, 93, e13032.	2.7	4
624	Metabolome and lipidome derangements during a severe mast cell activation event in a patient with indolent systemic mastocytosis. Journal of Allergy and Clinical Immunology, 2021, 148, 1533-1544.	2.9	4
625	Role of Mast Cells in Endogenous Fibrinolysis and Related (Patho)physiological Processes. , 2000, , 497-505.		4
626	c-kit D816V Provides a Strong Signal for Myelomastocytic Differentiation and Cluster Formation in Murine Ba/F3 Cells.. Blood, 2004, 104, 485-485.	1.4	4
627	Evidence for an Underestimation of the Prognostic Impact of Poor Cytogenetics within the IPSS.. Blood, 2006, 108, 252-252.	1.4	4
628	Nilotinib and Imatinib Are Comparably Effective in Reducing Growth of Human Eosinophil Leukemia Cells in a Newly Established Xenograft Model. PLoS ONE, 2012, 7, e30567.	2.5	4
629	An in vitro Model for the Allergenâ€“IgEâ€“FcÎµRI Interaction. International Archives of Allergy and Immunology, 1999, 118, 116-118.	2.1	3
630	Classification and Response Criteria in Mast Cell Disorders: Time to Revise?. International Archives of Allergy and Immunology, 2011, 155, 306-308.	2.1	3

#	Article	IF	Citations
631	Long-term follow-up after allogeneic stem cell transplantation in patients with myelodysplastic syndromes or secondary acute myeloid leukemia: a single center experience. Wiener Klinische Wochenschrift, 2014, 126, 23-29.	1.9	3
632	Clofarabine/cyclophosphamide for debulking before stem cell transplantation. European Journal of Clinical Investigation, 2014, 44, 775-783.	3.4	3
633	Diagnosis, management and response criteria of iron overload in myelodysplastic syndromes (MDS): updated recommendations of the Austrian MDS platform. Expert Review of Hematology, 2018, 11, 109-116.	2.2	3
634	The <scp>JAK</scp>2 blocker <scp>TG</scp>101209 is a potent inhibitor of clonogenic progenitor cell growth in patients with chronic myeloid leukaemia. British Journal of Haematology, 2018, 181, 137-139.	2.5	3
635	Clonal architecture in patients with myelodysplastic syndromes and double or minor complex abnormalities: Detailed analysis of clonal composition, involved abnormalities, and prognostic significance. Genes Chromosomes and Cancer, 2018, 57, 547-556.	2.8	3
636	Ludwig Boltzmann Cluster Oncology (LBC ONC): first 10Âyears and future perspectives. Wiener Klinische Wochenschrift, 2018, 130, 517-529.	1.9	3
637	A kinase profile-adapted drug combination elicits synergistic cooperative effects on leukemic cells carrying BCR-ABL1T315I in Ph+ CML. Leukemia Research, 2019, 78, 36-44.	0.8	3
638	Clinical, Hematologic, Biologic and Molecular Characteristics of Patients with Myeloproliferative Neoplasms and a Chronic Myelomonocytic Leukemia-Like Phenotype. Cancers, 2020, 12, 1891.	3.7	3
639	Myelomonocytic skewing in chronic myelomonocytic leukemia: phenotypic, molecular and biologic features and impact on survival. European Journal of Haematology, 2021, 106, 627-633.	2.2	3
640	Overexpression of PD-L1 Correlates with JAK2-V617F Mutational Burden and Is Associated with Chromosome 9p Uniparental Disomy in MPN. Blood, 2020, 136, 24-24.	1.4	3
641	New and Comprehensive Cytogenetic Prognostication and Categorization in MDS.. Blood, 2006, 108, 248-248.	1.4	3
642	Azacitidine in Acute Myeloid Leukemia: Comparison of Patients with AML-MRF Vs AML-NOS Enrolled in the Austrian Azacitidine Registry. Blood, 2014, 124, 3681-3681.	1.4	3
643	Impact of Molecular Markers on Response and Resistance in Midostaurin-Treated Patients with Advanced Systemic Mastocytosis. Blood, 2016, 128, 945-945.	1.4	3
644	Structural and utational nalysis of ember-pecific STAT unctions. Biochimica Et Biophysica Acta - General Subjects, 2022, 1866, 130058.	2.4	3
645	Forest land tax reductions â€“ an effective payment for forest ecosystem services in Slovakia?. Central European Forestry Journal, 2021, 67, 167-176.	0.8	3
646	Multistep pathogenesis of chronic myelomonocytic leukemia in patients. European Journal of Haematology, 2022, , .	2.2	3
647	Massive release of TH2 cytokines induced a cytokine storm during a severe mast cell activation event in a patient with indolent systemic mastocytosis. Journal of Allergy and Clinical Immunology, 2022, 150, 406-414.e16.	2.9	3
648	Reciprocal Translocation (3;5)(q26;q22) and Possible BCHE Gene Involvement in an Unusual Myelogenous Disorder with both Myeloproliferative and Dysplastic Features. Cancer Genetics and Cytogenetics, 2000, 121, 133-138.	1.0	2

#	Article	IF	Citations
649	Use of interleukin-11 to stimulate platelet production in myelodysplastic syndromes. Leukemia and Lymphoma, 2006, 47, 1999-2001.	1.3	2
650	Exploring the curative potential of BCRâ€“ABL1-targeting drugs for chronic myeloid leukaemia. Lancet Oncology, The, 2010, 11, 1010-1011.	10.7	2
651	Successful allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia during respiratory failure and invasive mechanical ventilation. Wiener Klinische Wochenschrift, 2011, 123, 354-358.	1.9	2
652	Glucocorticosteroids Rescue Basophils from Dasatinib-Augmented Immunoglobulin E-Mediated Histamine Release. International Archives of Allergy and Immunology, 2012, 159, 15-22.	2.1	2
653	Impact of <scp>PPM1D</scp> mutations in patients with myelodysplastic syndrome and deletion of chromosome 5q. American Journal of Hematology, 2021, 96, E207-E210.	4.1	2
654	Mastocytosis, MCAS, and Related Disordersâ€”Diagnosis, Classification, and Therapy. International Journal of Molecular Sciences, 2021, 22, 5024.	4.1	2
655	Case report of a clinically indolent but morphologically highâ€grade cutaneous mast cell tumor in an adult: atypical cutaneous mastocytoma or mast cell sarcoma?. Journal of Cutaneous Pathology, 2021, 48, 1404-1409.	1.3	2
656	The CDK4/6 Inhibitor Palbociclib Exerts Growth-Inhibitory Effects on Neoplastic Mast Cells and Synergizes with Midostaurin in Producing Growth Arrest. Blood, 2018, 132, 1363-1363.	1.4	2
657	Inhibition of Growth of Neoplastic Mast Cells by CD44 mAb A3D8 Is Associated with G1 Cell Cycle Arrest and Apoptosis.. Blood, 2005, 106, 3518-3518.	1.4	2
658	New Prognostic Data on Rare Cytogenetic Abnormalities in MDS: A Collaborative Study of the International Working Group on MDS Cytogenetics. Blood, 2008, 112, 2688-2688.	1.4	2
659	Serum Tryptase Is a Strong Predictive Biomarker That Improves Prognostication in Ph+ Chronic Myeloid Leukemia.. Blood, 2012, 120, 2783-2783.	1.4	2
660	Oncogene-Induced DNA Repair Defects Promote PARP1-Mediated â€œDual Synthetic Lethalityâ€•To Eradicate Quiescent and Proliferating Leukemia Stem and Progenitor Cells. Blood, 2013, 122, 810-810.	1.4	2
661	Inactivation of the SETD2 Tumor Suppressor Gene in Mast Cell Leukemia. Blood, 2014, 124, 1881-1881.	1.4	2
662	Azacitidine in Patients with Treatment-Related Acute Myeloid Leukemia: Retrospective Analysis of the Austrian Azacitidine Registry. Blood, 2014, 124, 2284-2284.	1.4	2
663	Azacitidine in Patients with Relapsed/Refractory Acute Myeloid Leukemia : Retrospective Analysis of the Austrian Azacitidine Registry. Blood, 2014, 124, 943-943.	1.4	2
664	Genome-Wide Molecular Portrait of Aggressive Systemic Mastocytosis and Mast Cell Leukemia Depicted By Whole Exome Sequencing and Copy Number Variation Analysis. Blood, 2015, 126, 4085-4085.	1.4	2
665	Mast Cell Leukemia: Clinical Heterogeneity, Molecular Aberrations, Treatment Responses, Survival, and Prognostic Factors. Blood, 2016, 128, 3109-3109.	1.4	2
666	Evaluation of Cell Surface Markers and Targets in Leukemic Stem Cells (LSC) Reveals Distinct Expression Profiles, Unique Drug Effects, and Specific Checkpoint Regulation in AML LSC and CML LSC. Blood, 2016, 128, 4234-4234.	1.4	2

#	Article	IF	Citations
667	Incidence and Prognostic Impact of Cytogenetics in Combination with Molecular Aberrations in Patients with Systemic Mastocytosis. Blood, 2016, 128, 947-947.	1.4	2
668	Mast cells and mast cell growth factor: possible role in auricular thrombosis. Biomedical Reviews, 2014, 4, 29.	0.6	2
669	Interleukin-9 (IL-9) and NPM-ALK each generate mast cell hyperplasia as single 'hit' and cooperate in producing a mastocytosis-like disease in mice. Oncotarget, 2010, 1, 104-19.	1.8	2
670	Degradation of BRD4 - a promising treatment approach not only for hematologic but also for solid cancer. American Journal of Cancer Research, 2021, 11, 530-545.	1.4	2
671	Asciminib and ponatinib exert synergistic anti-neoplastic effects on CML cells expressing -compound mutations. American Journal of Cancer Research, 2021, 11, 4470-4484.	1.4	2
672	Refinements in Response Criteria in Systemic Mastocytosis: Reply to a Proposal. European Journal of Haematology, 2010, 85, no-no.	2.2	1
673	Endogenous Erythroid Colony Formation in Chronic Myeloid Leukemia: A Recurrent Finding Associated with Persistent Minimal Residual Disease Under Imatinib. Stem Cells and Development, 2013, 22, 3043-3051.	2.1	1
674	Characterization and targeting of neoplastic stem cells in Ph+chronic myeloid leukemia. International Journal of Hematologic Oncology, 2015, 4, 151-165.	1.6	1
675	All systems red. American Journal of Hematology, 2015, 90, 356-360.	4.1	1
676	10th anniversary of the Austrian MDS Platform: aims and ongoing projects. Wiener Klinische Wochenschrift, 2015, 127, 12-15.	1.9	1
677	Is ruxolitinib a potentially useful drug in hematological malignancies with RAS pathway hyperactivation?. Haematologica, 2016, 101, e492-e492.	3.5	1
678	Major response of PNH to an AML chemotherapy protocol. Annals of Hematology, 2018, 97, 1487-1488.	1.8	1
679	Mast Cells and Mastocytosis. , 2018, , 1170-1186.		1
680	Comparison of BCR-ABL1 quantification in peripheral blood and bone marrow using an International Scale-standardized assay for assessment of deep molecular response in chronic myeloid leukemia. Clinical Chemistry and Laboratory Medicine, 2020, 58, 1214-1222.	2.3	1
681	Presence of viremia during febrile neutropenic episodes in patients undergoing chemotherapy for malignant neoplasms. American Journal of Hematology, 2021, 96, 719-726.	4.1	1
682	Induction of antibody responses to new B cell epitopes indicates vaccination character of allergen immunotherapy. , 0, .		1
683	Systemic Mastocytosis Associated with Lymphoproliferative Disorders (SM-AHNMD). , 2012, , 271-279.		1
684	A New Prognostic Score for Advanced Systemic Mastocytosis Based on Clinical and Genetic Characteristics of 210 Consecutive Patients. Blood, 2018, 132, 349-349.	1.4	1

#	Article	IF	Citations
685	Phenotypic Characterization of Leukemia-Initiating Stem Cells in Chronic Myelomonocytic Leukemia (CMML). Blood, 2019, 134, 4223-4223.	1.4	1
686	Treatment Guided By Next Generation Functional Drug Screening Provides Clinical Benefit in Advanced Aggressive Hematological Malignancies: Final Evaluation of the Open Label, Single Arm Exalt Trial. Blood, 2020, 136, 2-4.	1.4	1
687	The Heme Oxygenase-1-Targeting Compound PEG-ZnPP Inhibits Growth of Imatinib-Resistant BCR/ABL-Transformed Cells.. Blood, 2004, 104, 1986-1986.	1.4	1
688	Identification of Mcl-1 as a Novel Target in Neoplastic Mast Cells and Demonstration of Cooperative Growth-Inhibitory Effects of mcl-1 Antisense Oligonucleotides, PKC412, and AMN107.. Blood, 2005, 106, 3516-3516.	1.4	1
689	Heme Oxygenase-1 (HO-1): A Novel KIT D816V-Dependent Target in Neoplastic Human Mast Cells (HMC-1).. Blood, 2005, 106, 3521-3521.	1.4	1
690	Dasatinib (BMS354825) Inhibits IgE-Dependent Activation and Histamine Release in Human Blood Basophils.. Blood, 2006, 108, 1365-1365.	1.4	1
691	Phenotypic and Functional Characterization of CD34+/CD38-/CD123+ Leukemic Progenitor (Stem) Cells in AML: a Flow Cytometric Approach.. Blood, 2008, 112, 1340-1340.	1.4	1
692	The Midostaurin (PKC412) Metabolite CGP52421 Shows Little Growth-Inhibitory Activity Against Against Neoplastic Mast Cells but Retains Inhibitory Effects on IgE-Dependent Activation and Histamine Release. Blood, 2011, 118, 1417-1417.	1.4	1
693	Phenotyping Of Leukemic Stem Cells In Ph+ ALL and Ph- ALL Reveals Unique Profiles Of Markers and Targets In Distinct Disease Variants. Blood, 2013, 122, 1654-1654.	1.4	1
694	Incidence of Intensive Care Unit Admission, Outcome, and Post Intensive Care Survival in Patients with Acute Lymphocytic Leukemia or Burkitt Lymphoma. Blood, 2014, 124, 2633-2633.	1.4	1
695	A Phase I Study of Lenalidomide in Patients with Chronic Myelomonocytic Leukaemia (CMML) â€“ AGMT_CMML 1. Blood, 2014, 124, 3268-3268.	1.4	1
696	Azacitidine in Patients with Acute Myeloid Leukemia: Assessing the Potential Negative Impact of Elevated Baseline White Blood Cell Count on Outcome. Blood, 2014, 124, 3683-3683.	1.4	1
697	Prognostic Impact of Rare Single Abnormalities in Myelodysplastic Syndromes. Blood, 2015, 126, 2879-2879.	1.4	1
698	Histidine Decarboxylase (HDC) as Novel Marker of Immature Neoplastic Mast Cells in Systemic Mastocytosis.. Blood, 2004, 104, 4755-4755.	1.4	1
699	Phenotyping of Neoplastic (CD34+/CD38â˜’/CD123+) Stem Cells in Myeloid Malignancies Reveals Expression of Multiple Molecular Targets.. Blood, 2005, 106, 1381-1381.	1.4	1
700	Mastocytosis â€“ A Disease of the Hematopoietic Stem Cell: In reply. Deutsches Ärzteblatt International, 0, , .	0.9	1
701	Partial Characterization and In Vitro Expansion of Putative CLL Precursor/Stem Cells Which Are Dependent on Bone Marrow Microenvironment for Survival. Blood, 2010, 116, 2433-2433.	1.4	1
702	Diagnostic Criteria and Classification of Myelodysplastic Syndromes. , 2011, , 43-53.		1

#	Article	IF	Citations
703	The Genomic and Transcriptomic Landscape of Systemic Mastocytosis. Blood, 2016, 128, 3136-3136.	1.4	1
704	Secondary basophilic leukemia in Ph-negative myeloid neoplasms: A distinct subset with poor prognosis. Neoplasia, 2021, 23, 1183-1191.	5.3	1
705	TET2 and DNMT3A Mutations Exert Divergent Effects on DNA Repair and Sensitivity of Leukemia Cells to PARP Inhibitors. Blood, 2020, 136, 4-4.	1.4	1
706	Impact of interest rates on forest management planning based on multi-criteria decision analysis. Central European Forestry Journal, 2022, 68, 23-35.	0.8	1
707	Efficacy and Synergy of Small Molecule Inhibitors Targeting FLT3-ITD+ Acute Myeloid Leukemia. Cancers, 2021, 13, 6181.	3.7	1
708	Targets and targeted drugs in chronic myeloid leukemia. Leukemia and Lymphoma, 2008, 49, 599-599.	1.3	0
709	Clinical impact of genetic and molecular markers in myelodysplastic syndromes (MDS). Memo - Magazine of European Medical Oncology, 2009, 2, 13-17.	0.5	0
710	Classification and response criteria in mastocytosis: is there a need to revise?. Expert Review of Hematology, 2010, 3, 247-249.	2.2	0
711	Systemic mastocytosis. , 2012, , 369-378.		0
712	The Austrian Competence Network on Mastocytosis (AUCNM): a partner and part of the European ECNM network. Memo - Magazine of European Medical Oncology, 2013, 6, 114-118.	0.5	0
713	Peripheral arterial disease outcomes and association with suPAR: AÂbridge to myeloid precursors or mast cells or both?. Atherosclerosis, 2017, 264, 77-78.	0.8	0
714	Cover Image, Volume 16, Issue 1. Veterinary and Comparative Oncology, 2018, 16, i.	1.8	0
715	Eosinophilia, Eosinophil-Associated Diseases, Eosinophilic Leukemias, and the Hypereosinophilic Syndromes. , 2018, , 1151-1169.		0
716	Additional prognostic impact of the percentage of erythroid cells in the bone marrow of patients with myelodysplastic syndromes. Leukemia Research, 2019, 77, 8-13.	0.8	0
717	AÂmulticenter retrospective evaluation of Chronic Myeloid Leukemia (CML) therapy in Austria assessing the impact of early treatment response on patient outcomes in aÂreal-life setting. Wiener Klinische Wochenschrift, 2020, 132, 415-422.	1.9	0
718	Clinical Course and Prognosis in Mast Cell Proliferative Disorders: A 17 Year Experience in a Single Center.. Blood, 2004, 104, 4741-4741.	1.4	0
719	Enumeration and Immunologic Characterization of Basophils in Normal Bone Marrow and Patients with Myeloproliferative Disorders.. Blood, 2004, 104, 4754-4754.	1.4	0
720	Low-Level Expression of the Tumor Suppressor Bim in CML Cells: Role of BCR/ABL, Delineation of Underlying Signaling Pathways, and Re-Expression by Imatinib, AMN107, and Proteasome Inhibitors.. Blood, 2005, 106, 1987-1987.	1.4	0

#	Article	IF	Citations
721	Prognostic Significance of Serial Determinations of LDH Levels in Primary (De Novo) Myelodysplastic Syndromes.. Blood, 2006, 108, 4828-4828.	1.4	0
722	Prognostic Factors Predicting Survival in De Novo AML Patients Requiring Intensive Care.. Blood, 2007, 110, 2860-2860.	1.4	0
723	The Plk-1 Inhibitor BI 2536 Counteracts the Growth of Neoplastic Mast Cells and Synergizes with the KIT D816V-Targeting Drug Midostaurin (PKC412) in Producing Growth-Inhibition.. Blood, 2007, 110, 3554-3554.	1.4	0
724	Liposomal Cytarabine (DepoCyte) for Treatment of Myeloid CNS Relapse in CML Occurring during Therapy with Imatinib.. Blood, 2007, 110, 4556-4556.	1.4	0
725	Spectrum, Function, and Value of Targets Expressed in Neoplastic Mast Cells. , 2009, , 107-125.		0
726	Effects of the Mcl-1/Bcl-2 Inhibitor GX015-070 (ObatoclaxÂ®) on Growth and Viability of Canine and Human Neoplastic Mast Cells. Blood, 2008, 112, 861-861.	1.4	0
727	Revealing Six Phases of CML Stem Cell Development to Explain Clinical Phenomena Seen in TKI-Treated Patients.. Blood, 2009, 114, 4263-4263.	1.4	0
728	BCR/ABL+ CML Stem Cells (CD34+/CD38-) Express High Levels of CD33 and Are Responsive to a CD33-Targeting Drug: a New Potential Concept for Eradication of CML Stem Cells.. Blood, 2010, 116, 3382-3382.	1.4	0
729	Karyotype Plus NPM1 Mutation Status Defines a Group of Elderly Patients with AML (â‰¥60 Years) Who Benefit From Intensive Post-Induction Consolidation Therapy. Blood, 2011, 118, 2504-2504.	1.4	0
730	Identification of Campath-1 Antigen (CD52) As a Novel Therapeutic Target in Advanced Systemic Mastocytosis.. Blood, 2012, 120, 2866-2866.	1.4	0
731	Effects of Ponatinib and Other Novel TKI On Growth, Survival, and Function of Neoplastic Eosinophils Carrying FIP1L1/Pdgfra. Blood, 2012, 120, 1760-1760.	1.4	0
732	Clofarabine/Cyclophosphamide (ClofCy) for Debulking refractory Acute Leukemias Prior to Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2012, 120, 4504-4504.	1.4	0
733	Next Generation Sequencing Identifies DNA Methylation Patterns Indicative of Disease Progression in Ph+ CML. Blood, 2014, 124, 4526-4526.	1.4	0
734	Molecular Profiling of Myeloid Progenitor Cells in Multi-Mutated Advanced Systemic Mastocytosis Identifies KIT D816V As a Distinct and Late Event. Blood, 2014, 124, 3216-3216.	1.4	0
735	Gene Expression and Mutation Analysis (GEMA) â€“Guided Precision Medicine Targeting PARP1 to Induce Synthetic Lethality in DNA-PK â€“Deficient Quiescent and BRCA-Deficient Proliferating Leukemia Stem and Progenitor Cells. Blood, 2014, 124, 480-480.	1.4	0
736	Maintenance with Histamine and IL-2 Induces a Marked Expansion of Activated CD56bright NK Cells in Acute Myeloid Leukemia. Blood, 2014, 124, 1422-1422.	1.4	0
737	Paul Ehrlich (1854-1915) and the Birth of Molecular Medicine. , 2015, 12, .		0
738	Identification of the Epigenetic Reader BRD4 As a Novel Potential Target in Ph+ CML. Blood, 2015, 126, 1571-1571.	1.4	0

#	Article	IF	Citations
739	Mastozytosen. , 2019, , 95-113.		0
740	History and Current Status of Mastocytosis Research in the European Competence Network on Mastocytosis. , 2020, , 287-299.		0
741	Isolation and Culture of Mast Cells and Basophils. , 2002, , 241-257.		0
742	Impact of gene variants on iron overload, overall survival and leukemia-free survival in myelodysplastic syndromes. American Journal of Cancer Research, 2021, 11, 955-967.	1.4	0
743	Core Binding Factor Leukemias Utilize a Physiologic Sense/Antisense Promoter Switch Employed By T-Cells. Blood, 2020, 136, 40-41.	1.4	0
744	Phenotyping of Disease-Initiating CD34+/CD38â”€ Stem Cells in BCR-ABL1â”€ MPN Reveals Expression of Multiple Cytokine Receptors and Resistance-Related Antigens. Blood, 2020, 136, 53-53.	1.4	0
745	Perspective: Pivotal translational hematology and therapeutic insights in chronic myeloid hematopoietic stem cell malignancies. Hematological Oncology, 2022, 40, 491-504.	1.7	0
746	Reply to â€œNeed to define a subgroup of patients with idiopathic mast cell activation syndromeâ€. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 1128.	3.8	0
747	PI3-kinase inhibition as a strategy to suppress the leukemic stem cell niche in Ph+ chronic myeloid leukemia.. American Journal of Cancer Research, 2021, 11, 6042-6059.	1.4	0
748	CDK4/CDK6 Inhibitors Synergize with Midostaurin, Avapritinib, and Nintedanib in Inducing Growth Inhibition in KIT D816V+ Neoplastic Mast Cells. Cancers, 2022, 14, 3070.	3.7	0